+

US20060019988A1 - Compounds, compositions, and methods - Google Patents

Compounds, compositions, and methods Download PDF

Info

Publication number
US20060019988A1
US20060019988A1 US11/188,287 US18828705A US2006019988A1 US 20060019988 A1 US20060019988 A1 US 20060019988A1 US 18828705 A US18828705 A US 18828705A US 2006019988 A1 US2006019988 A1 US 2006019988A1
Authority
US
United States
Prior art keywords
optionally substituted
alkyl
hydrogen
chosen
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/188,287
Inventor
Andrew McDonald
Pu-Ping Lu
Gustave Bergnes
David Morgans
Dashyant Dhanak
Steven Knight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc, SmithKline Beecham Corp filed Critical Cytokinetics Inc
Priority to US11/188,287 priority Critical patent/US20060019988A1/en
Publication of US20060019988A1 publication Critical patent/US20060019988A1/en
Assigned to CYTOKINETICS, INCORPORATED reassignment CYTOKINETICS, INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SMITHKLINE BEECHAM CORPORATION
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms

Definitions

  • the invention relates to methods for treating cellular proliferative diseases, and for treating disorders by inhibiting the activity of KSP.
  • the methods employ compounds represented by Formula I: wherein,
  • R 4 is chosen from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, and optionally substituted heteroaralkyl;
  • R 5 , R 6 , R 7 and R 8 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted alkoxy, halogen, hydroxyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, optionally substituted aryl and optionally substituted heteroaryl;
  • R 17 is chosen from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl;
  • the present invention provides methods of screening for compounds that will bind to a KSP kinesin, for example compounds that will displace or compete with the binding of a compound of the invention.
  • the methods comprise combining a labeled compound of the invention, a KSP kinesin, and at least one candidate assent and determining the binding of the candidate agent to the KSP kinesin.
  • HMDS hexamethyldisilazane
  • HOBt hydroxybenzotriazole
  • NMO N-methylmorpholine oxide
  • PEG polyethylene glycol
  • PPTS pyridinium p-toluenesulfonate
  • Aminocarbonyl- refers to the group —NR c COR b , —NR c CO 2 R a , or —NR c CONR b R c , where
  • guanidine —NR c CR b NR b R c , —CNR c NR b R c , —C 1 -C 4 alkyl-NH 2 , —N(C 1 -C 4 alkyl)(C 1 -C 4 alkyl), —NH(C 1 -C 4 alkyl), —N(C 1 -C 4 alkyl)(C 1 -C 4 alkylphenyl), —NH(C 1 -C 4 alkylphenyl), cyano, nitro, oxo (as a substituent for heteroaryl), —CO 2 H, —C(O)OC 1 -C 4 alkyl-, —CON(C 1 -C 4 alkyl)(C 1 -C 4 alkyl), —CONH(C 1 -C 4 alkyl), —CONH 2 , —NHC(O)(C 1 -C 4 alkyl), —NHC(O
  • each optionally substituted R b group is independently unsubstituted or substituted with one or more substituents independently selected from C 1 -C 4 alkyl-, aryl-, heterocyclyl-, aryl-C 1 -C 4 alkyl-, heteroaryl-C 1 -C 4 alkyl-, C 1 -C 4 haloalkyl-, —OC 1 -C 4 alkyl-, —OC 1 -C 4 alkylphenyl-, —C 1 -C 4 alkyl-OH, —OC 1 -C 4 haloalkyl-, halogen, —OH, —NH 2 , —C 1 -C 4 alkyl-NH 2 , —N(C 1 -C 4 alkyl)(C 1 -C 4 alkyl), —NH(C 1 -C 4 alkyl), —N(C 1 -C 4 alkyl)(C 1 -C 4 alkylphenyl), —
  • Heterocyclyl means a cycloalkyl or aryl residue in which one to foul of the carbons is replaced by a heteroatom such as oxygen, nitrogen or sulfur.
  • heterocycles that fall within the scope of the invention include azetidinyl-, imidazolinyl-, pyrrolidinyl-, pyrazolyl-, pyrrolyl-, indolyl-, quinolinyl-, isoquinolinyl-, tetrahydroisoquinolinyl-, benzofuranyl-, benzodioxanyl-, benzodioxyl (commonly referred to as methylenedioxyphenyl-, when occurring as a substituent), tetrazolyl-, morpholinyl-, thiazolyl-, pyridinyl-, pyridazinyl-, piperidinyl-, pyrimidinyl-, thienyl-, furanyl-
  • R a is an optionally substituted C 1 -C 6 alkyl-, aryl-, heteroaryl-, aryl-C 1 -C 4 alkyl-, or heteroaryl-C 1 -C 4 alkyl- group,
  • Sulfinyl refers to the groups: —S(O)—H, —S(O)-(optionally substituted alkyl), —S(O)-optionally substituted aryl), —S(O)-(optionally substituted heteroaryl), —S(O)-(optionally substituted heterocyclyl); and —S(O)-(optionally substituted amino).
  • Protecting group has the meaning conventionally associated with it in organic synthesis, i.e. a group that selectively blocks one or more reactive sites in a multifunctional compound such that a chemical reaction can be carried out selectively on another unprotected reactive site and such that the group can readily be removed after the selective reaction is complete.
  • a variety of protecting groups are disclosed, for example, in T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, Third Edition, John Wiley & Sons, New York (1999), which is incorporated herein by reference in its entirety.
  • a hydroxy protected form is where at least one of the hydroxyl groups present in a compound is protected with a hydroxy protecting group.
  • amities and other reactive groups may similarly be protected.
  • Solvate refers to the compound formed by the interaction of a solvent and a compound of Formula I or salt thereof, and as will be understood by those skilled in the art, is the compound or salt with which a solvent is incorporated, for example, into the crystal structure.
  • Suitable solvates of the compounds of the Formula I or a salt thereof are those formed with a pharmaceutically acceptable solvent, including hydrates (i.e., wherein the solvent is water).
  • the R— and S-isomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallization; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent.
  • a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent.
  • enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
  • the present invention is directed to a class of novel compounds, that can be described as isoquinolone derivatives, that are inhibitors of one or more mitotic kinesins.
  • mitotic kinesins By inhibiting mitotic kinesins, but not other kinesins (e.g., transport kinesins), specific inhibition of cellular proliferation is accomplished.
  • the present invention capitalizes on the finding that perturbation of mitotic kinesin function causes malformation or dysfunction of mitotic spindles, frequently resulting in cell cycle arrest and cell death.
  • the compounds described herein inhibit the mitotic kinesin, KSP, particularly human KSP.
  • the compounds inhibit the mitotic kinesin, KSP, as well as modulating one or more of the human mitotic kinesins selected from the group consisting of HSET (see, U.S. Pat. No. 6,361,993, which is incorporated herein by reference); MCAK (see, U.S. Pat. No. 6,331,424, which is incorporated herein by reference); CENP-E (see, PCT Publication No. WO 99/13061, which is incorporated herein by reference); Kif4 (see, U.S. Pat. No. 6,440,684, which is incorporated herein by reference); MKLP1 (see, U.S. Pat. No.
  • the methods of inhibiting a mitotic kinesin comprise contacting an inhibitor of the invention with a kinesin, particularly a human kinesin, more particularly, human KSP or fragments and variants thereof.
  • the inhibition can be of the ATP hydrolysis activity of the KSP kinesin and/or the mitotic spindle formation activity, such that the mitotic spindles are disrupted. Meiotic spindles may also be disrupted.
  • the present invention provides inhibitors of mitotic kinesins, in particular KSP and especially human KSP, for the treatment of disorders associated with cell proliferation.
  • the compounds, compositions and methods described herein can differ in their selectivity and are used to treat diseases of cellular proliferation, including, but not limited to cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders, fungal disorders and inflammation.
  • R 1 is chosen from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl;
  • R 3b is chosen from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl;
  • R 15 is chosen from optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl;
  • R 17 is chosen from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl;
  • the compounds of Formula I can be named and numbered in the manner described below (e.g., using AutoNom version 2.1 in ISIS-DRAW or ChemDraw).
  • the compound i.e., the compound according to Formula I where R 1 is benzyl-, R 2 is propyl (or i-propyl), R 2′ is hydrogen; R 12 is substituted imidazolinyl wherein R 10 and R 10′ are methyl, R 11 and R 11′ are hydrogen and R 14 is p-tolyl; R 5 , R 6 , and R 8 are hydrogen; and R 7 is chloro
  • q.s. means adding a quantity sufficient to achieve a stated function, e.g., to bring a solution to the desired volume (i.e., 100%).
  • esters of carboxylic acids may be prepared by conventional esterification procedures, for example alkyl esters may be prepared by treating the required carboxylic acid with the appropriate alkanol, generally under acidic conditions.
  • amides may be prepared using conventional amidation procedures, for example amides may be prepared by treating an activated carboxylic acid with the appropriate amine.
  • a lower-alkyl ester such as a methyl ester of the acid may be treated with an amine to provide the required amide, optionally in presence of trimethylalluminium following the procedure described in Tetrahedron Lett. 48, 4171-4173, (1977).
  • Carboxyl groups may be protected as alkyl esters, for example methyl esters, which esters may be prepared and removed using conventional procedures, one convenient method for converting carbomethoxy to carboxyl is to use aqueous lithium hydroxide.
  • a desired base addition salt can be prepared by treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary); an alkali metal or alkaline earth metal hydroxide; or the like.
  • an inorganic or organic base such as an amine (primary, secondary, or tertiary); an alkali metal or alkaline earth metal hydroxide; or the like.
  • suitable salts include organic salts derived from amino acids such as glycine and arginine; ammonia; primary, secondary, and tertiary amines; such as ethylenediamine, and cyclic amines, such as cyclohexylamine, piperidine, morpholine, and piperazine; as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
  • amino acids such as glycine and arginine
  • ammonia primary, secondary, and tertiary amines
  • primary, secondary, and tertiary amines such as ethylenediamine, and cyclic amines, such as cyclohexylamine, piperidine, morpholine, and piperazine
  • inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
  • the compounds of Formula I can be prepared by following the procedures described in U.S. patent application Ser. No. 10/366,828 and corresponding PCT Application No. US03/04713; and PCT Publication Nos. WO 01/30768 and WO 01/98278, each of which is incorporated herein by reference for all purposes, and with reference to the Reaction Schemes below.
  • Reaction Scheme 1 illustrates a synthesis of an intermediate (i.e., compounds of Formula 113) in the synthesis of compounds of Formula I.
  • Reaction Scheme 2 illustrates a synthesis of compounds of Formula I wherein R 12 is —N(R 4 )(COR 3 ) from compounds of Formula 113.
  • Reaction Scheme 3 shows a synthesis of compounds of Formula I wherein R 12 is —N(R 4 )(SO 2 R 3a ) from compounds of Formula 203.
  • Reaction Scheme 5 shows a synthesis of compounds of Formula I wherein R 12 is optionally substituted imidazolyl from compounds of Formula 113.
  • Reaction Scheme 6 shows a synthesis of compounds of Formula I wherein R 12 is optionally substituted imidazolyl from compounds of Formula 113.
  • Reaction Scheme 7 shows a synthesis of compounds of Formula I wherein R 12 is optionally substituted imidazolinyl from compounds of Formula 113.
  • Reaction Scheme 8 shows a synthesis of compounds of Formula I wherein R 12 is optionally substituted imidazolinyl from compounds of Formula 705.
  • Reaction Scheme 9 shows a synthesis of compounds of Formula I wherein R 12 is —N(R 4 )(COR 3 ) and R 3 is —OR 15 , from compounds of Formula 203.
  • a compound of Formula 103 is coupled to a compound of Formula 104.
  • reaction conditions can be used to effect this coupling, e.g., Sonogashira coupling conditions using a palladium catalyst such as (diphenylphosphineferrocenyl)dichloropalladium or tris(dibenzylidenacetone)-dipalladium; a base such as cesium carbonate or triethylamine; and ligands such as triphenylarsine or triphenylphosphine; Stille conditions using a palladium catalyst such as tris(dibenzylidinacetone)-dipalladium; lithium chloride; and triphenylarsine; or Suzuki coupling conditions wherein the compound of Formula 104 is treated with a borane such as catechol borane or 9-borabicyclo[3.3.1]nonane and the two fragments are coupled using a palladium catalyst such as those described above, a base
  • a mixture of a compound of Formula 103; a slight excess (preferably about 1.1 equivalents) of an acetylenic compound of Formula 104; a palladium catalyst such as dichlorobis(triphenylphosphine)palladium(II) and preferably about 0.025 equivalents of the catalyst; and cuprous iodide in a base such as triethylamine is heated at about 50° C.
  • the corresponding, optionally substituted compound of Formula 105 is isolated and purified.
  • the protecting group is then removed from the carboxylic acid.
  • the protecting group is a lower alkyl ester, it can be removed by treatment with aqueous alcoholic base at an elevated temperature.
  • methyl esters can be converted to the corresponding carboxylic acid by treatment of the ester with potassium hydroxide in a 1:1:1 solution of methanol, THF, and alcohol at about 50° C. for 30 minutes.
  • the corresponding, optionally substituted compound of Formula 107 is isolated and used without further purification.
  • Step 5 a solution of isochromen-1-one of Formula 109 and an excess (preferably about 3 equivalents) of a primary amine of formula R 1 NH 2 in a nonpolar solvent such as toluene is heated at reflux, preferably about 140° C.
  • a nonpolar solvent such as toluene
  • the resulting amide is isolated and dissolved in a polar, protic solvent such as methanol.
  • Aqueous acid preferably about 5% aqueous hydrochloric acid is added to the solution which is then heated to about 50° C. Additional aqueous alcholic acid may be added if required to complete the reaction.
  • the corresponding, optionally substituted 2H-isoquinolin-1-one of Formula 111 is isolated and purified.
  • Step 2 to a solution of a compound of Formula 203 and an amine base such as diisopropylethylamine in a nonpolar, aprotic solvent such as dichloromethane is added an R 3 acyl chloride (such as Cl—C(O)—R 3 where R 3 is as described above). The resulting solution is stirred under nitrogen at room temperature for several hours. The product, a compound of Formula 205 is isolated and purified.
  • an acyl chloride such as Cl—C(O)—R 3 where R 3 is as described above.
  • Step 2 to an optionally substituted compound of Formula 503 in an inert solvent (such as dichloromethane) in the presence of about 1.5 molar equivalents of an amine base (such as triethylamine) is added about 1.5 molar equivalents of an R 9 acid chloride, such as, Cl—C(O)—R 9 , where R 9 is as described above.
  • an inert solvent such as dichloromethane
  • an amine base such as triethylamine
  • R 9 acid chloride such as, Cl—C(O)—R 9
  • Step 3 a solution of a compound of Formula 505 and an excess of ammonium acetate in acetic acid is heated at reflux for 1-4 hours. Completion is monitored, e.g., by TLC. The corresponding compound of Formula 507 is isolated and purified. Preparation of Formula 603
  • Step 1 a suspension of a compound of Formula 113, an alpha-haloketone reagent of the Formula R 13′ (CO)CH 2 X wherein X is a leaving group (such as a halide) and R 13′ is as described herein, and about an equivalent of a base, such as potassium carbonate in a polar, aprotic solvent such as DMF is stirred at room temperature.
  • a base such as potassium carbonate in a polar, aprotic solvent such as DMF
  • Step 1 reductive amination of amines of Formula 113 (prepared as described in WO 0130768) with an optionally substituted, aldehyde-containing carbamic acid ester (Seki et. al. Chem. Pharm. Bull. 1996, 44, 2061) gives urethane intermediates. Removal of the Boc protecting group furnishes an amine of Formula 705.
  • aprotic solvent such as dichloromethane
  • an excess preferably about two equivalents of an amine base, such as triethylamine, followed by about an equivalent of an acid chloride of formula R 14 COCl.
  • the resultant solution is stirred at ambient temperature for 2 hours, then evaporated under reduced pressure.
  • the resultant solid is treated with glacial acetic acid, then the resultant suspension is heated at reflux for about 48 hours.
  • the reaction is cooled to ambient temperature then evaporated under reduced pressure.
  • the corresponding compound of Formula 709 is isolated and purified.
  • a compound of Formula 203 is treated with a slight excess of an isocyanate R 17 —N ⁇ C ⁇ O in the presence of a base, such as triethylamine, in a nonpolar, aprotic solvent, such as dichloromethane.
  • a base such as triethylamine
  • a nonpolar, aprotic solvent such as dichloromethane
  • Step 1 to a solution of a compound of Formula 113 and an excess of an optionally substituted, aldehyde-containing, carbamic acid ester such as ((S)-4-benzyloxycarbonylamino-1-formyl-butyl)-carbamic acid tert-butyl ester) in a nonpolar, aprotic solvent such as CH 2 Cl 2 is added sodium triacetoxyborohydride. The mixture is strirred overnight. The product, a compound of Formula 1203, is isolated and purified.
  • an optionally substituted, aldehyde-containing, carbamic acid ester such as ((S)-4-benzyloxycarbonylamino-1-formyl-butyl)-carbamic acid tert-butyl ester
  • aprotic solvent such as CH 2 Cl 2
  • Step 3 a solution of a compound of Formula 1205 in a solvent such as CH 2 Cl 2 /TFA (preferably, about 4:1 CH 2 Cl 2 /TFA) is stirred at room temperature.
  • a solvent such as CH 2 Cl 2 /TFA (preferably, about 4:1 CH 2 Cl 2 /TFA)
  • the reaction mixture is concentrated under reduced pressure and the residue is diluted with a nonpolar, aprotic solvent such as CH 2 Cl 2 and washed with aqueous base.
  • the aqueous layer is extracted with a nonpolar, aprotic solvent such as CH 2 Cl 2 and the combined extracts are dried, filtered and concentrated under reduced pressure.
  • the residue is diluted with a nonpolar, aprotic solvent such as THF and aqueous base (preferably, saturated aqueous NaHCO 3 ).
  • the mixture is stirred at room temperature for 10 days.
  • the product, a compound of Formula 1207 is isolated and purified.
  • a compound of Formula 505, 605, 705, or 707 is optionally cyclized by acid-mediated cyclization.
  • a racemic mixture of isomers of a compound of Formula I is optionally placed on a chromatography column and separated into (R)— and (S)-enantiomers.
  • a compound of Formula I is optionally contacted with a pharmaceutically acceptable acid or base to form the corresponding acid or base addition salt.
  • a pharmaceutically acceptable acid addition salt of a compound of Formula I is optionally contacted with a base to form the corresponding free base of Formula I.
  • R 1 is selected from hydrogen, optionally substituted C 1 -C 8 alkyl-, optionally substituted aryl-, optionally substituted heteroaryl-, optionally substituted aryl-C 1 -C 4 -alkyl-, and optionally substituted heteroaryl-C 1 -C 4 -alkyl- (more particularly optionally substituted aryl and optionally substituted aryl-C 1 -C 4 -alkyl-).
  • R 1 is selected from hydrogen, optionally substituted C 1 -C 4 alkyl-, optionally substituted phenyl-C 1 -C 4 -alkyl-, optionally substituted naphthalenylmethyl-, optionally substituted phenyl-, and naphthyl-. Even more particularly, R 1 is optionally substituted phenyl-C 1 -C 4 -alkyl-, optionally substituted heteroaryl-C 1 -C 4 -alkyl-, or naphthalenylmethyl-.
  • R 1 is naphthyl-, phenyl-, bromophenyl-, chlorophenyl-, methoxyphenyl-, ethoxyphenyl-, tolyl-, dimethylphenyl-, chorofluorophenyl-, methylchlorophenyl-, ethylphenyl-, phenethyl-, benzyl-, chlorobenzyl-, methylbenzyl-, methoxybenzyl-, cyanobenzyl-, hydroxybenzyl-, dichlorobenzyl-, dimethoxybenzyl-, or naphthalenylmethyl-. More suitably, R 1 is benzyl-, cyanobenzyl-, methoxybenzyl-, or naphthalenylmethyl-. Most particularly, R 1 is benzyl-.
  • the compounds described herein possess a potentially chiral center at the carbon to which R 2 and R 2′ are attached.
  • the R 2 and R 2′ groups may be the same or different; if different, the compound is chiral (i.e., has a stereogenic center).
  • R 2 and R 2′ are different, in particular embodiments R 2′ is hydrogen and R 2 is other than hydrogen.
  • the invention contemplates the use of pure enantiomers and mixtures of enantiomers, including racemic mixtures, although the use of a substantially optically pure enantiomer will generally be preferred.
  • substantially pure means having at least about 95% chemical purity with no single impurity greater than about 1%.
  • substantially optically pure or “enantiomerically pure” means having at least about 97.5% enantiomeric excess.
  • the stereogtenic center to which R 2 and R 2′ are attached is of the R configuration.
  • R 2 and R 2′ are independently chosen from hydrogen, optionally substituted alkyl-, optionally substituted alkoxy, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, and optionally substituted heteroaralkyl-.
  • R 2 is optionally substituted C 1 -C 4 alkyl-
  • R 2′ is hydrogen or optionally substituted C 1 -C 4 alkyl-. More suitably, R 2′ is hydrogen and R 2 is optionally substituted C 1 -C 4 alkyl-.
  • R 2 is chosen from methyl-, ethyl-, propyl (particularly, c-propyl or i-propyl), butyl (particularly, t-butyl), methylthioethyl-, methylthiomethyl-, aminobutyl-, (CBZ)aminobutyl-, cyclohexylmethyl-, benzyloxymethyl-, methylsulfanylethyl-, methylsulfanylmethyl-, and hydroxymethyl-, and R 2′ is hydrogen.
  • R 2′ is hydrogen and R 2 is ethyl or propyl (particularly, c-propyl or i-propyl).
  • R 2 is i-propyl.
  • the stereogenic center to which R 2 and R 2′ is attached is of the R configuration.
  • R 2 or R 2′ are hydrogen, then the other is not hydrogen. In another embodiment, both R 2 and R 2′ are hydrogen.
  • R 5 , R 6 , R 7 , and R 8 are independently chosen from hydrogen, hydroxyl, halogen (particularly chloro and fluoro), optionally substituted C 1 -C 4 alkyl- (particularly methyl-), C 1 -C 4 alkoxy (particularly methoxy), cyano, amino, substituted amino, or carbamyl-. More particularly, R 5 , R 6 , R 7 , and R 8 are methoxy, methyl, trifluoromethyl, cyano, hydrogen or halo.
  • R 5 is hydrogen or halo
  • R 6 is hydrogen, optionally substituted C 1 -C 4 alkyl- (particularly, methyl-) or halo
  • R 7 is hydrogen, halo, optionally substituted C 1 -C 4 alkyl- (particularly, methyl- or trifluoromethyl-), C 1 -C 4 alkoxy (particularly, methoxy), cyano, substituted amino, or carbamyl-
  • R 8 is hydrogen, C 1 -C 4 alkyl- (particularly, methyl-), C 1 -C 4 alkoxy (particularly, methoxy), hydroxy, or halo.
  • Still more particularly are the compounds where only one of R 5 , R 6 , R 7 , and R 8 is not hydrogen, especially R 7 .
  • Another particular embodiment is drawn to the compounds where R 7 and R 8 are not hydrogen.
  • R 12 is an Optionally Substituted Imidazolyl
  • R 12 is an optionally substituted imidazolyl-, in particular embodiments, R 12 has the formula: wherein
  • R 9 is chosen from hydrogen, optionally substituted C 1 -C 8 alkyl-, optionally substituted aryl-, optionally substituted aryl-C 1 -C 4 -alkyl-, optionally substituted heteroaryl-C 1 -C 4 -alkyl-, optionally substituted aryl-C 1 -C 4 -alkoxy, optionally substituted heteroaryl-C 1 -C 4 -alkoxy, and optionally substituted heteroaryl-; and
  • R 9 is lower-alkyl; phenyl substituted with optionally substituted C 1 -C 4 -alkyl-, C 1 -C 4 -alkoxy-, and/or halo; phenyl-; benzyl-; thiophenyl-; or thiophenyl- substituted with C 1 -C 4 -alkyl-, C 1 -C 4 -alkoxy-, and/or halo. More suitably, R 9 is lower-alkyl; phenyl-; or phenyl- substituted with one or more of the following groups: methyl, methoxy, trifluoromethyl, or halo.
  • R 13 is hydrogen and R 13′ is substituted C 1 -C 4 alkyl-. More suitably, R 13 is hydrogen and R 13′ is aminomethyl-, aminoethyl-, aminopropyl-, acetylamino-methyl-, acetylaminoethyl-, benzyloxycarbonylamino-methyl- or benzyloxycarbonylamino-ethyl-.
  • R 12 is an Optionally Substituted Imidazolinyl
  • R 14 is chosen from hydrogen, optionally substituted C 1 -C 8 alkyl-, optionally substituted aryl-, optionally substituted aryl-C 1 -C 4 -alkyl-, optionally substituted heteroaryl-, optionally substituted heteroaryl-C 1 -C 4 -alkyl-; and
  • R 10 , R 10′ , R 11 and R 11′ are independently chosen from hydrogen, optionally substituted C 1 -C 8 alkyl-, optionally substituted aryl-, and optionally substituted aryl-C 1 -C 4 -alkyl-.
  • R 14 is lower-alkyl-; methylenedioxyphenyl-; phenyl-; phenyl substituted with optionally substituted C 1 -C 4 alkyl-, C 1 -C 4 alkoxy-, and/or halo; benzyl-; thienyl substituted with C 1 -C 4 alkyl; benzyl; thiophenyl-; or thiophenyl- substituted with C 1 -C 4 -alkyl-, C 1 -C 4 -alkoxy-, and/or halo. More suitably, R 14 is lower-alkyl; phenyl-; or phenyl- substituted with one or more of the following groups: methyl, methoxy, trifluoromethyl, or halo.
  • R 12 is —NHR 4 , —NR 4 (COR 3 ), NR 4 (SO 2 R 3a ), or —NR 4 (CH 2 R 3b ) R 4
  • R 4 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, and optionally substituted heterocyclyl-. More suitably, R 4 is R 16 -alkylene-, and R 16 is chosen from alkoxy, amino, alkylamino, dialkylamino, carboxy, guanidine, hydroxyl-, and N-heterocyclyl-.
  • R 4 is selected from optionally substituted lower-alkyl-, optionally substituted cyclohexyl-; phenyl substituted with hydroxy, lower-alkoxy or lower-alkyl-; benzyl-; heteroarylmethyl-; heteroarylethyl-; and heteroarylpropyl-.
  • R 3 when R 3 is not R 17 NH— or R 15 O—, R 3 is chosen from optionally substituted alkyl-; aryl- (including phenyl-, biphenyl-, and naphthyl-); substituted aryl- (including phenyl substituted with one or more cyano, halo, lower-alkyl-, lower-alkoxy, hydroxy-loweralkyl-, nitro, carboxy, methylenedioxy, trifluoromethoxy, or trifluoromethyl-); benzyl-; and optionally substituted heteroaryl-.
  • aryl- including phenyl-, biphenyl-, and naphthyl-
  • substituted aryl- including phenyl substituted with one or more cyano, halo, lower-alkyl-, lower-alkoxy, hydroxy-loweralkyl-, nitro, carboxy, methylenedioxy, trifluoromethoxy, or trifluoromethyl-
  • R 3 is tolyl-, halophenyl-, halomethylphenyl-, hydroxymethylphenyl-, methylenedioxyphenyl-, formylphenyl or cyanophenyl-.
  • R 17 is chosen from lower-alkyl-; cyclohexyl-; phenyl-; and phenyl substituted with halo, lower-alkyl-, loweralkoxy, or lower-alkylsulfanyl-.
  • R 15 is isopropyl-, butyl-, cyclohexyl-, phenyl-, bromophenyl-, dichlorophenyl-, methoxyphenyl-, ethylphenyl-, tolyl-, trifluoromethylphenyl or methylthiophenyl-.
  • R 4 is as described above and R 3a is chosen from C 1 -C 13 alkyl-; phenyl-; naphthyl-; phenyl substituted-with cyano, halo, lower-alkyl-, lower-alkoxy, nitro, methylenedioxy, or trifluoromethyl-; biphenylyl and heteroaryl-. More suitably, R 3a is chosen from phenyl substituted with halo, lower-alkyl-, lower-alkoxy, cyano, nitro, methlenedioxy, or trifluoromethyl-; and naphthyl-.
  • R 1 , R 2 , R 2′ , R 5 , R 6 , R 7 , and R 8 are as defined above;
  • R 1 , R 2 , R 2′ , R 5 , R 6 , R 7 , and R 8 are as defined above;
  • Particular compounds include:
  • the compounds of the invention are used to treat cellular proliferation diseases.
  • diseases which can be treated by the compounds, compositions and methods provided herein include, but are not limited to, cancer (further discussed below), autoimmune disease, fungal disorders, arthritis, graft rejection, inflammatory bowel disease, cellular proliferation induced after medical procedures, including, but not limited to, surgery, angioplasty, and the like.
  • Treatment includes inhibiting cellular proliferation. It is appreciated that in some cases the cells may not be in an abnormal state and still require treatment.
  • the invention herein includes application to cells or individuals afflicted or subject to impending affliction with any one of these disorders or states.
  • KSP or a compound according to the invention is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g., a microtiter plate, an array, etc.).
  • the insoluble support may be made of any material to which the sample can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening.
  • the surface of such supports may be solid or porous and of any convenient shape.
  • suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, TeflonTM, etc.
  • In vivo screening methods include assays of cell cycle distribution, cell viability, or the presence, morphology, activity, distribution, or number of mitotic spindles.
  • Methods for monitoring cell cycle distribution of a cell population are well known to those skilled in the art, as are methods for determining cell viability. See for example, U.S. Pat. No. 6,437,115, hereby incorporated by reference in its entirety.
  • Microscopic methods for monitoring spindle formation and malformation are well known to those of skill in the art (see, e.g., Whitehead and Rattner (1998), J. Cell Sci. 111:2551-61; Galgio et al, (1996) J. Cell Biol., 135:399-414), each incorporated herein by reference in its entirety.
  • the compounds of the invention inhibit the KSP kinesin.
  • One measure of inhibition is IC 50 , defined as the concentration of the compound at which the activity of KSP is decreased by fifty percent relative to a control.
  • Preferred compounds have IC 50 's of less than about 1 mM, with preferred embodiments having IC 50 's of less than about 100 ⁇ M, with more preferred embodiments having, IC 50 's of less than about 10 ⁇ M, with particularly preferred embodiments having IC 50 's of less than about 1 ⁇ M, and especially preferred embodiments having IC 50 's of less than about 100 nM, and with the most preferred embodiments having IC 50 's of less than about 10 nM.
  • Measurement of IC 50 is done using an ATPase assay such as described herein.
  • K i Another measure of inhibition is K i .
  • the K i or K d is defined as the dissociation rate constant for the interaction of the compounds described herein with KSP.
  • Preferred compounds have K i 's of less than about 100 ⁇ M, with preferred embodiments having K i 's of less than about 10 ⁇ M, and particularly preferred embodiments having K i 's of less than about 1 ⁇ M and especially preferred embodiments having K i 's of less than about 100 nM, and with the most preferred embodiments having K i 's of less than about 10 nM.
  • the K i for a compound is determined from the IC 50 based on three assumptions and the Michaelis-Menten equation. First, only one compound molecule binds to the enzyme and there is no cooperativity. Second, the concentrations of active enzyme and the compound tested are known (i.e., there are no significant amounts of impurities or inactive forms in the preparations). Third, the enzymatic rate of the enzyme-inhibitor complex is zero.
  • V V max ⁇ E 0 [ I - ( E 0 + I 0 + Kd ) - ( E 0 + I 0 + Kd ) 2 - 4 ⁇ E 0 ⁇ I 0 2 ⁇ E 0 ]
  • V the observed rate
  • V max the rate of the free enzyme
  • I 0 the inhibitor concentration
  • E 0 the enzyme concentration
  • K d the dissociation constant of the enzyme-inhibitor complex.
  • GI 50 defined as the concentration of the compound that results in a decrease in the rate of cell growth by fifty percent.
  • Preferred compounds have GI 50 's of less than about 1 mM; those having a GI 50 of less than about 20 ⁇ M are more preferred; those having a GI 50 of less than about 10 ⁇ M more so; those having a GI 50 of less than about 1 ⁇ M more so; those having a GI 50 of less than about 100 nM more so; and those having a GI 50 of less than about 10 nM even more so.
  • Measurement of GI 50 is done using a cell proliferation assay such as described herein. Compounds of this class were found to inhibit cell proliferation.
  • In vitro potency of small molecule inhibitors is determined, for example, by assaying human ovarian cancer cells (SKOV3) for viability following a 72-hour exposure to a 9-point dilution series of compound.
  • Cell viability is determined by measuring the absorbance of formazon, a product formed by the bioreduction of MTS/PMS, a commercially available reagent. Each point on the dose-response curve is calculated as a percent of untreated control cells at 72 hours minus background absorption (complete cell kill).
  • the KSP is bound to a support, and a compound of the invention is added to the assay.
  • the compound of the invention is bound to the support and KSP is added.
  • Classes of compounds among which novel binding agents may be sought include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for candidate agents that have a low toxicity for human cells.
  • tile compound is labeled, for example, with a fluorescent or radioactive moiety, and binding is determined directly. For example, this may be done by attaching all or a portion of KSP to a solid support, adding a labeled test compound (for example a compound of the invention in which at least one atom has been replaced by a detectable isotope), washing off excess reagent, and determining whether the amount of the label is that present on the solid support.
  • a labeled test compound for example a compound of the invention in which at least one atom has been replaced by a detectable isotope
  • label herein is meant that the compound is either directly or indirectly labeled with a label which provides a detectable signal, e.g., radioisotope, fluorescent tag, enzyme, antibodies, particles such as magnetic particles, chemiluminescent tag, or specific binding molecules, etc.
  • Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc.
  • the complementary member would normally be labeled with a molecule which provides for detection, in accordance with known procedures, as outlined above.
  • the label can directly or indirectly provide a detectable signal.
  • the kinesin proteins may be labeled at tyrosine positions using 125 I, or with fluorophores.
  • more than one component may be labeled with different labels; using 125 I for the proteins, for example, and a fluorophor for the antimitotic agents.
  • the compounds of the invention may also be used as competitors to screen for additional drug candidates.
  • “Candidate agent” or “drug candidate” or grammatical equivalents as used herein describe any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for bioactivity. They may be capable of directly or indirectly altering the cellular proliferation phenotype or the expression of a cellular proliferation sequence, including both nucleic acid sequences and protein sequences. In other cases, alteration of cellular proliferation protein binding and/or activity is screened. Screens of this sort may be performed either in the presence or absence of microtubules.
  • exogenous agents include candidate agents which do not bind the cellular proliferation protein in its endogenous native state termed herein as “exogenous” agents.
  • exogenous agents further exclude antibodies to KSP.
  • Candidate agents can encompass numerous chemical classes, though typically they are organic molecules, preferably they are small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons.
  • Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding and lipophilic binding, and typically include at least an amine, carbonyl-, hydroxyl-, ether, or carboxyl group, preferably at least two of the functional chemical groups.
  • the candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups.
  • Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof.
  • Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, and/or amidification to produce structural analogs.
  • the binding of the candidate agent to KSP is determined through the use of competitive binding assays.
  • the competitor is a binding moiety known to bind to KSP, such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding as between the candidate agent and the binding moiety, with the binding moiety displacing the candidate agent.
  • the candidate agent is labeled. Either the candidate agent, or the competitor, or both, is added first to KSP for a time sufficient to allow binding, if present. Incubations may be performed at-any temperature which facilitates optimal activity, typically between 4 and 40° C.
  • Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high throughput screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.
  • the competitor is added first, followed by the candidate agent.
  • Displacement of the competitor is an indication the candidate agent is binding to KSP and thus is capable of binding to, and potentially inhibiting, the activity of KSP.
  • either component can be labeled.
  • the presence of label in the wash solution indicates displacement by the agent.
  • the candidate agent is labeled, the presence of the label on the support indicates displacement.
  • Inhibition is tested by screening for candidate agents capable of inhibiting the activity of KSP comprising the steps of combining a candidate agent with KSP, as above, and determining an alteration in the biological activity of KSP.
  • the candidate agent should both bind to KSP (although this may not be necessary), and alter its biological or biochemical activity as defined herein.
  • the methods include both in vitro screening methods and in vivo screening of cells for alterations in cell cycle distribution, cell viability, or for the presence, morpohology, activity, distribution, or amount of mitotic spindles, as are generally outlined above.
  • differential screening may be used to identify drug candidates that bind to the native KSP, but cannot bind to modified KSP.
  • Positive controls and negative controls may be used in the assays.
  • Suitably all control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, all samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.
  • reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g., albumin, detergents, etc which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in any order that provides for the requisite binding.
  • the compounds of the invention are administered to cells.
  • administered herein is meant administration of a therapeutically effective dose of a compound of the invention to a cell either in cell culture or in a patient.
  • therapeutically effective dose herein is meant a dose that produces the effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques. As is known in the art, adjustments for systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art.
  • cells herein is meant any cell in which mitosis or meiosis can be altered.
  • a “patient” for the purposes of the present invention includes both humans and other animals, particularly mammals, and other organisms. Thus the methods are applicable to both human therapy and veterinary applications.
  • the patient is a mammal, and more particularly, the patient is human.
  • Compounds of the invention having the desired pharmacological activity may be administered, generally as a pharmaceutically acceptable composition comprising an pharmaceutical excipient, to a patient, as described herein.
  • the compounds may be formulated in a variety of ways as discussed below.
  • the concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt. %.
  • the agents may be administered alone or in combination with other treatments, i.e., radiation, or other chemotherapeutic agents such as the taxane class of agents that appear to act on microtubule formation or the camptothecin class of topoisomerase I inhibitors.
  • other chemotherapeutic agents may be administered before, concurrently, or after administration of a compound of the present invention.
  • a compound of the present invention is co-administered with one or more other chemotherapeutic agents.
  • co-administer it is meant that the present compounds are administered to a patient such that the present compounds as well as the co-administered compound may be found in the patient's bloodstream at the same time, regardless when the compounds are actually administered including simultaneously.
  • the administration of the compounds and compositions of the present invention can be done in a variety of ways, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly.
  • the compound or composition may be directly applied as a solution or spray.
  • Pharmaceutical dosage forms include a compound of formula I or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof, and one or more pharmaceutical excipients.
  • pharmaceutical excipients are secondary ingredients which function to enable or enhance the delivery of a drug or medicine in a variety of dosage forms (e.g.: oral forms such as tablets, capsules, and liquids; topical forms such as dermal, opthalmic, and otic forms; suppositories; injectables; respiratory forms and the like).
  • Pharmaceutical excipients include inert or inactive ingredients, synergists or chemicals that substantively contribute to the medicinal effects of the active ingredient.
  • pharmaceutical excipients may function to improve flow characteristics, product uniformity, stability, taste, or appearance, to ease handling and administration of dose, for convenience of use, or to control bioavailability. While pharmaceutical excipients are commonly described as being inert or inactive, it is appreciated in the art that there is a relationship between the properties of the pharmaceutical excipients and the dosage forms containing them.
  • compositions for intravenous administration will generally comprise intravenous fluids, i.e., sterile solutions of simple chemicals such as sugars, amino acids or electrolytes, which can be easily carried by the circulatory system and assimilated.
  • intravenous fluids i.e., sterile solutions of simple chemicals such as sugars, amino acids or electrolytes, which can be easily carried by the circulatory system and assimilated.
  • Such fluids are prepared with water for injection USP.
  • dextrose and water e.g., 5% dextrose
  • dextrose and water e.g., 5% dextrose
  • NSS normal saline solution
  • ammonium chloride e.g., 2.14%
  • dextran 70 in NSS e.g., 6% or in D5/W e.g., 6%;
  • dextrose glucose, D5/W
  • Glucose D5/W
  • dextrose and sodium chloride e.g., 5-20% dextrose and 0.22-0.9% NaCl;
  • mannitol e.g., 5%, optionally in combination with dextrose e.g., 10% or NaCl e.g., 15 or 20%;
  • electrolyte solutions with varying combinations of electrolytes, dextrose, fructose, invert sugar Ringer's e.g., NaCl 0.86%, KCl 0.03%, CaCl 2 0.033%;
  • sodium bicarbonate e.g., 5%
  • sodium chloride e.g. 0.45, 0.9, 3, or 5%
  • Pd(MeCN) 2 Cl 2 (98mg, 0.39 mmol) was added to a solution of the crude acid 5 (2.76 g, 7.87 mmol), TEA (3.3 mL) and THF (54 mL). The solution was maintained at 50° C. for 30 mins. The reaction solution was diluted with hexanes (150 mL) and passed through a plug of silica gel. The plus was rinsed with (5:1 hexanes:EtOAc). The filtrate was concentrated. Hexanes (50 mL) was added to this crude residue and pure 6 precipitated out of solution. This precipitated material was filtered and used without further purification.
  • Cells are plated in 96-well plates at densities from 1000-2500 cells/well of a 96-well plate and allowed to adhere/grow for 24 hours. They are then treated with various concentrations of drug for 48 hours. The time at which compounds are added is considered T 0 .
  • KSP inhibitors inhibit cell proliferation in human ovarian tumor cell lines (SKOV-3).
  • Solution 1 consists of 3 mM phosphoenolpyruvate potassium salt (Sigma P-7127), 2 mM ATP (Sigma A-3377), 1 mM IDTT (Sigma D-9779), 5 ⁇ M paclitaxel (Sigma T-7402), 10 ppm antifoam 289 (Sigma A-8436), 25 mM Pipes/KOH pH 6.8 (Sigma P6757), 2 mM MgCl2 (VWR JT400301), and 1 mM EGTA (Sigma E3889).
  • Solution 1 consists of 3 mM phosphoenolpyruvate potassium salt (Sigma P-7127), 2 mM ATP (Sigma A-3377), 1 mM IDTT (Sigma D-9779), 5 ⁇ M paclitaxel (Sigma T-7402), 10 ppm antifoam 289 (Sigma A-8436), 25 mM Pipes/KOH pH 6.8 (Sigma P6757), 2
  • Serial dilutions (8-12 two-fold dilutions) of the compounds are made in a 96-well microtiter plate (Corning Costar 3695) using Solution 1. Following serial dilution each well has 50 ⁇ l of Solution 1. The reaction is started by adding 50 ⁇ l of Solution 2 to each well. This may be done with a multichannel pipettor either manually or with automated liquid handling devices. The microtiter plate is then transferred to a microplate absorbance reader and multiple absorbance readings at 340 nm are taken for each well in a kinetic mode. The observed rate of change, which is proportional to the ATPase rate, is then plotted as a function of the compound concentration.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.

Description

    CROSS-REFERENCE TO RELATED PATENT APPLICATIONS
  • This application claims the benefit of U.S. Provisional Patent Application No. 60/389,265, filed Jun. 14, 2002 and of U.S. Provisional Patent Application No. 60/389,779, filed Jun. 18, 2002; each of which is incorporated herein by reference for all purposes.
    • FIELD OF THE INVENTION
  • This invention relates to compounds which are inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders, fungal disorders, and inflammation.
    • BACKGROUND OF THE INVENTION
  • Among the therapeutic agents used to treat cancer are the taxanes and vinca alkaloids, which act on microtubules. Microtubules are the primary structural element of the mitotic spindle. The mitotic spindle is responsible for distribution of replicate copies of the genome to each of the two daughter cells that result from cell division. It is presumed that disruption of the mitotic spindle by these drugs results in inhibition of cancer cell division, and induction of cancer cell death. However, microtubules form other types of cellular structures, including tracks for intracellular transport in nerve processes. Because these agents do not specifically target mitotic spindles, they have side effects that limit their usefulness.
  • Improvements in the specificity of agents used to treat cancer is of considerable interest because of the therapeutic benefits which would be realized if the side effects associated with the administration of these agents could be reduced. Traditionally, dramatic improvements in the treatment of cancer are associated with identification of therapeutic agents acting through novel mechanisms. Examples of this include not only the taxanes, but also the camptothecin class of topoisomerase 1 inhibitors. From both of these perspectives, mitotic kinesins are attractive targets for new anti-cancer agents.
  • Mitotic kinesins are enzymes essential for assembly and function of the mitotic spindle, but are not generally part of other microtubule structures, such as in nerve processes. Mitotic kinesins play essential roles during all phases of mitosis. These enzymes are “molecular motors” that transform energy released by hydrolysis of ATP into mechanical force which drives the directional movement of cellular cargoes along microtubules. The catalytic domain sufficient for this task is a compact structure of approximately 340 amino acids. During mitosis, kinesins organize microtubules into the bipolar structure that is the mitotic spindle. Kinesins mediate movement of chromosomes along spindle microtubules, as well as structural changes in the mitotic spindle associated with specific pleases of mitosis. Experimental perturbation of mitotic kinesin function causes malformation or dysfunction of the mitotic spindle, frequently resulting in cell cycle arrest and cell death.
  • Among the mitotic kinesins which have been identified is KSP. KSP belongs to an evolutionarily conserved kinesin subfamily of plus end-directed microtubule motors that assemble into bipolar homotetramers consisting of antiparallel homodimers. During mitosis KSP associates with microtubules of the mitotic spindle. Microinjection of antibodies directed against KSP into human cells prevents spindle pole separation during prometaphase, giving rise to monopolar spindles and causing mitotic arrest and induction of programmed cell death. KSP and related kinesins in other, non-human, organisms, bundle antiparallel microtubules and slide them relative to one another, thus forcing the two spindle poles apart. KSP may also mediate in anaphase B spindle elongation and focussing of microtubules at the spindle pole.
  • Human KSP (also termed HsEg5) has been described (Blangy, et al., Cell, 83:1159-69 (1995); Whitehead, et al., Arthritis Rheum., 39:1635-42 (1996); Galgio et al., J. Cell Biol., 135:339-414 (1996); Blangy, et al., J Biol. Chem., 272:19418-24 (1997); Blangy, et al., Cell Motil Cytoskeleton, 40:174-82 (1998); Whitehead and Rattner, J. Cell Sci., 111:2551-61 (1998); Kaiser, et al., JBC 274:18925-31 (1999); GenBank accession numbers: X85137, NM004523 and U37426), and a fragment of the KSP gene (TRIP5) has been described (Lee, et al., Mol Endocrinol., 9:243-54 (1995); GenBank accession number L403 72). Xenopus KSP homologs (Eg5), as well as Drosophila KLP61 F/KRP1 30 have been reported.
  • Mitotic kinesins, including KSP, are attractive targets for the discovery and development of novel antimitotic chemotherapeutics. Accordingly, it is an object of the present invention to provide compounds, compositions and methods useful in the inhibition of KSP.
    • SUMMARY OF THE INVENTION
  • In accordance with the objects outlined above, the present invention provides compounds that can be used to treat cellular proliferative diseases The compounds are KSP inhibitors, particularly human KSP inhibitors. The present invention also provides compositions comprising such compounds, and methods utilizing such compounds or compositions, which can be used to treat cellular proliferative diseases
  • In one aspect, the invention relates to methods for treating cellular proliferative diseases, and for treating disorders by inhibiting the activity of KSP. The methods employ compounds represented by Formula I:
    Figure US20060019988A1-20060126-C00001
    wherein,
  • R1 is chosen from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl;
  • R2 and R2′ are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; or R2 and R2′ taken together form an optionally substituted 3- to 7-membered ring;
  • R12 is selected from the group consisting of optionally substituted imidazolyl, optionally substituted imidazolinyl, —NHR4; —N(R4)(COR3); —N(R4)(SO2R3a); and —N(R4)(CH2R3b);
  • R3 is chosen from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, R15O— and R17—NH—;
  • R3a is chosen from optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, and R17—NH—;
  • R3b is chosen from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl;
  • R4 is chosen from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, and optionally substituted heteroaralkyl;
  • R5, R6, R7 and R8 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted alkoxy, halogen, hydroxyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, optionally substituted aryl and optionally substituted heteroaryl;
  • R15 is chosen from optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and
  • R17 is chosen from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl;
  • (Formula I including single stereoisomers and mixtures of stereoisomers);
  • a pharmaceutically acceptable salt of a compound of Formula I;
  • a pharmaceutically acceptable solvate of a compound of Formula I; or
  • a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt of a compound of Formula I.
  • In one aspect, the invention relates to methods for treating cellular proliferative diseases and other disorders that can be treated by inhibiting KSP by the administration of a therapeutically effective amount of a compound of Formula I; a pharmaceutically acceptable salt of a compound of Formula I; a pharmaceutically acceptable solvate of a compound of Formula I; or a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt of a compound of Formula I. Such diseases and disorders include cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders, fungal disorders and inflammation. It will be understood that the method can employ one or more of the foregoing compounds.
  • In another aspect, the invention relates to compounds useful in inhibiting KSP kinesin. The compounds are selected from compounds having tile structures shown above in Formula I; pharmaceutically acceptable salts of a compound of Formula I; pharmaceutically acceptable solvates of a compound of Formula I; and pharmaceutically acceptable solvates of a pharmaceutically acceptable salt of a compound of Formula I. The invention also relates to pharmaceutical compositions comprising: a therapeutically effective amount of a compound of Formula I; a pharmaceutically acceptable salt of a compound of Formula I; a pharmaceutically acceptable solvate of a compound of Formula I; or a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt of a compound of Formula I; and one or more pharmaceutical excipients. It will be understood that the compositions can employ one or more of the foregoing compounds. In another aspect, the composition further comprises a chemotherapeutic agent other than a compound of the present invention.
  • In an additional aspect, the present invention provides methods of screening for compounds that will bind to a KSP kinesin, for example compounds that will displace or compete with the binding of a compound of the invention. The methods comprise combining a labeled compound of the invention, a KSP kinesin, and at least one candidate assent and determining the binding of the candidate agent to the KSP kinesin.
  • In a further aspect, the invention provides methods of screening for modulators of KSP kinesin activity. The methods comprise combining a compound of the invention, a KSP kinesin, and at least one candidate agent and determining the effect of the candidate agent on the KSP kinesin activity.
    • DETAILED DESCRIPTION OF THE INVENTION DEFINITIONS
  • As used in the present specification, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise. The following abbreviations and terms have the indicated meanings throughout:
  • Ac=acetyl
  • BNB=4-bromomethyl-3-nitrobenzoic acid
  • Boc=t-butyloxy carbonyl
  • Bu=butyl
  • c-=cyclo
  • CBZ=carbobenzoxy=benzyloxycarbonyl
  • DBU=diazabicyclo[5.4.0]undec-7-ene
  • DCM=dichloromethane=methylene chloride=CH2Cl2
  • DCE=dichloroethane
  • DEAD=diethyl azodicarboxylate
  • DIC=diisopropylcarbodiimide
  • DIEA=N,N-diisopropylethylamine
  • DMAP=4-N,N-dimethylaminopyridine
  • DMF=N,N-dimethylformamide
  • DMSO=dimethyl sulfoxide
  • DVB=1,4-divinylbenzene
  • EEDQ=2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline
  • Et=ethyl
  • Fmoc=9-fluorenylmethoxycarbonyl
  • GC=gas chromatography
  • HATU=O-(7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
  • HMDS=hexamethyldisilazane
  • HOAc=acetic acid
  • HOBt=hydroxybenzotriazole
  • Me=methyl
  • mesyl=methanesulfonyl
  • MTBE=methyl t-butyl ether
  • NMO=N-methylmorpholine oxide
  • PEG=polyethylene glycol
  • Ph=phenyl
  • PhOH=phenol
  • PfP=pentafluorophenol
  • Pht=phthalyl
  • PPTS=pyridinium p-toluenesulfonate
  • Py=pyridine
  • PyBroP=bromo-tris-pyrrolidino-phosphonium hexafluorophosphate
  • rt=room temperature
  • sat'd=saturated
  • s-=secondary
  • t-=tertiary
  • TBDMS=t-butyldimethylsilyl
  • TES=triethylsilyl
  • TFA=trifluoroacetic acid
  • THF=tetrahydrofuran
  • TMOF=trimethyl orthoformate
  • TMS=trimethylsilyl
  • tosyl=p-toluenesulfonyl
  • Trt=triphenylmethyl
  • Alkyl is intended to include linear, branched, or cyclic aliphatic hydrocarbon structures and combinations thereof, which structures may be saturated or unsaturated. Lower-alkyl refers to alkyl groups of from 1 to 5 carbon atoms, preferably from 1 to 4 carbon atoms. Examples of lower-alkyl groups include methyl-, ethyl-, propyl-, isopropyl-, butyl-, s- and t-butyl and tile like. Preferred alkyl groups are those of C20 or below. More preferred alkyl groups are those of C13 or below. Cycloalkyl is a subset of alkyl and includes cyclic aliphatic hydrocarbon groups of from 3 to 13 carbon atoms. Examples of cycloalkyl groups include c-propyl-, c-butyl, c-pentyl-, norbornyl-, adamantyl and the like. Cycloalkyl-alkyl- is another subset of alkyl and refers to cycloalkyl attached to the parent structure through a non-cyclic alkyl-. Examples of cycloalkyl-alkyl- include cyclohexylmethyl-, cyclopropylmethyl-, cyclohexylpropyl-, and the like. In this application, alkyl includes alkanyl-, alkenyl and alkynyl residues; it is intended to include vinyl-, allyl-, isoprenyl and the like. When an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, “butyl” is meant to include n-butyl-, sec-butyl-, isobutyl and t-butyl-; “propyl” includes n-propyl-, isopropyl-, and c-propyl-.
  • Alkylene-, alkenylene-, and alkynylene- are other subsets of alkyl-, including the same residues as alkyl-, but having two points of attachment within a chemical structure. Examples of alkylene include ethylene (—CH2CH2—), propylene (—CH2CH2CH2—), dimethylpropylene (—CH2C(CH3)2CH2—) and cyclohexylpropylene (—CH2CH2CH(C6H13)—). Likewise, examples of alkenylene include ethenylene (—CH═CH—), propenylene (—CH═CH—CH2—), and cyclohexylpropenylene (—CH═CHCH(C6H13)—). Examples of alkynylene include ethynylene (—C═C—) and propynylene (—CH═CH—CH2—).
  • Cycloalkenyl is a subset of alkyl and includes unsaturated cyclic hydrocarbon groups of from 3 to 13 carbon atoms. Examples of cycloalkenyl groups include c-hexenyl-, c-pentenyl and the like.
  • Alkoxy or alkoxyl refers to an alkyl group, preferably including from 1 to 8 carbon atoms, of a straight, branched, or cyclic configuration, or a combination thereof, attached to the parent structure through an oxygen (i.e., the group alkyl-O—). Examples include methoxy-, ethoxy-, propoxy-, isopropoxy-, cyclopropyloxy-, cyclohexyloxy- and the like. Lower-alkoxy refers to alkoxy groups containing one to four carbons.
  • Acyl refers to groups of from 1 to 8 carbon atoms of a straight, branched, or cyclic configuration or a combination thereof attached to the parent structure through a carbonyl functionality. Such groups may be saturated or unsaturated, and aliphatic or aromatic. One or more carbons in the acyl residue may be replaced by oxygen, nitrogen (e.g., carboxamido), or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl-, benzoyl-, propionyl-, isobutyryl-, oxalyl-, t-butoxycarbonyl-, benzyloxycarbonyl, morpholinylcarbonyl, and the like. Lower-acyl refers to acyl groups containing one to four carbons.
  • Amino refers to the group —NH2. The term “substituted amino” refers to the group —NHR or —NRR where each R is independently selected from the group: optionally substituted alkyl-, optionally substituted alkoxy, optionally substituted aminocarbonyl-, optionally substituted aryl-, optionally substituted heteroaryl-, optionally substituted heterocyclyl-, acyl-, alkoxycarbonyl-, sulfanyl-, sulfinyl and sulfonyl-, e.g., diethylamino, methylsulfonylamino, furanyl-oxy-sulfonamino.
  • Aminocarbonyl- refers to the group —NRcCORb, —NRcCO2Ra, or —NRcCONRbRc, where
  • R1 is optionally substituted C1-C6 alkyl-, aryl-, heteroaryl-, aryl-C1-C4 alkyl-, or heteroaryl-C1-C4 alkyl- group;
  • Rb is H or optionally substituted C1-C6 alkyl-, aryl-, heteroaryl-, aryl-C1-C4 alkyl-, or heteroaryl-C1-C4 alkyl- group; and
  • Rc is hydrogen, alkyl-; aryl- or heteroaryl-; and where each optionally substituted Rb group is independently unsubstituted or substituted with one or more substituents independently selected from C1-C4 alkyl-, aryl-, heterocyclyl-, aryl-C1-C4 alkyl-, heteroaryl-C1-C4 alkyl-, C1-C4 haloalkyl-, —OC1-C4 alkyl, —OC1-C4 alkylphenyl, —C1-C4 alkyl-OH, —OC1-C4 haloalkyl, halogen, —OH, —NH2, —NRcC(NRb)(NRbRc) (i.e. guanidine), —NRcCRbNRbRc, —CNRcNRbRc, —C1-C4 alkyl-NH2, —N(C1-C4 alkyl)(C1-C4 alkyl), —NH(C1-C4 alkyl), —N(C1-C4 alkyl)(C1-C4 alkylphenyl), —NH(C1-C4 alkylphenyl), cyano, nitro, oxo (as a substituent for heteroaryl), —CO2H, —C(O)OC1-C4 alkyl-, —CON(C1-C4 alkyl)(C1-C4 alkyl), —CONH(C1-C4 alkyl), —CONH2, —NHC(O)(C1-C4 alkyl), —NHC(O)(phenyl), —N(C1-C4 alkyl)C(O)(C1-C4 alkyl), —N(C1-C4 alkyl)C(O)(phenyl), —C(O)C1-C4 alkyl-, —C(O)C1-C4 phenyl-, —C(O)C1-C4 haloalkyl-, —OC(O)C1-C4 alkyl-, —SO2(C1-C4 alkyl), —SO2(phenyl), —SO2(C1-C4 haloalkyl), —SO2NH2, —SO2NH(C1-C4 alkyl), —SO2NH(phenyl), —NHSO2(C1-C4 alkyl), —NHSO2(phenyl), and —NHSO2(C1-C4 haloalkyl).
  • Antimitotic refers to a drug for inhibiting or preventing mitosis, for example, by causing metaphase arrest. Some antitumour drugs block proliferation and are considered antimitotics.
  • Aryl and heteroaryl mean a 5- or 6-membered aromatic or heteroaromatic ring containing 0 or 1-4 heteroatoms, respectively, selected from O, N, or S; a bicyclic 9- or 10-membered aromatic or heteroaromatic ring system containing 0 or 1-4 (or more) heteroatoms, respectively, selected from O, N, or S; or a tricyclic 12- to 14-membered aromatic or heteroaromatic ring system containing 0 or 1-4 (or more) heteroatoms, respectively, selected from O, N, or S. The aromatic 6- to 14-membered carbocyclic rings include, e.g., phenyl-, naphthyl-, indanyl-, tetralinyl-, and fluorenyl and the 5- to 10-membered aromatic heterocyclic rings include, e.g., imidazolyl-, pyridinyl-, indolyl-, thienyl-, benzopyranonyl-, thiazolyl-, furanyl-, benzimidazolyl-, quinolinyl-, isoquinolinyl-, quinoxalinyl-, pyrimidinyl-, pyrazinyl-, tetrazolyl and pyrazolyl-.
  • Aralkyl- refers to a residue in which an aryl moiety is attached to the parent structure via an alkyl residue. Examples include benzyl-, phenethyl-, phenylvinyl-, phenylallyl and the like. Heteroaralkyl- refers to a residue in which a heteroaryl moiety is attached to the parent structure via an alkyl residue. Examples include furanylmethyl-, pyridinylmethyl-, pyrimidinylethyl and the like.
  • Aralkoxy- refers to the group —O-aralkyl. Similarly, heteroaralkoxy- refers to the group —O-heteroaralkyl-; aryloxy- refers to the group —O-aryl-; acyloxy- refers to the group —O-acyl-; heteroaryloxy- refers to the group —O-heteroaryl-; and heterocyclyloxy- refers to the group —O-heterocyclyl (i.e., aralkyl-, heteroaralkyl-, aryl-, acyl-, heterocyclyl-, or heteroaryl is attached to the parent structure through an oxygen).
  • Carboxyalkyl- refers to the group -alkyl-COOH.
  • Carboxamido refers to the group —CONRbRc, where
  • Rb is H or optionally substituted C1-C6 alkyl-, aryl-, heteroaryl-, aryl-C1-C4 alkyl-, or heteroaryl-C1-C4 alkyl- group; and
  • Rc is hydrogen, alkyl-; aryl- or heteroaryl-; and
  • where each optionally substituted Rb group is independently unsubstituted or substituted with one or more substituents independently selected from C1-C4 alkyl-, aryl-, heterocyclyl-, aryl-C1-C4 alkyl-, heteroaryl-C1-C4 alkyl-, C1-C4 haloalkyl-, —OC1-C4 alkyl-, —OC1-C4 alkylphenyl-, —C1-C4 alkyl-OH, —OC1-C4 haloalkyl-, halogen, —OH, —NH2, —C1-C4 alkyl-NH2, —N(C1-C4 alkyl)(C1-C4 alkyl), —NH(C1-C4 alkyl), —N(C1-C4 alkyl)(C1-C4 alkylphenyl), —NH(C1-C4 alkylphenyl), cyano, nitro, oxo (as a substituent for heteroaryl), —CO2H, —C(O)OC1-C4 alkyl-, —CON(C1-C4 alkyl)(C1-C4 alkyl), —CONH(C1-C4 alkyl), —CONH2, —NHC(O)(C1-C4 alkyl), —NHC(O)(phenyl), —N(C1-C4 alkyl)C(O)(C1-C4 alkyl), —N(C1-C4 alkyl)C(O)(phenyl), —C(O)C1-C4 alkyl-, —C(O)C1-C4 phenyl-, —C(O)C1-C4 haloalkyl-, —OC(O)C1-C4 alkyl-, —SO2(C1-C4 alkyl), —SO2(phenyl), —SO2(C1-C4 haloalkyl), —SO2NH2, —SO2NH(C1-C4 alkyl), —SO2NH(phenyl), —NHSO2(C1-C4 alkyl), —NHSO2(phenyl), and —NHSO2(C1-C4 haloalkyl). Carboxamido is meant to include carbamoyl-; lower-alkyl carbamoyl-; benzylcarbamoyl-; phenylcarbamoyl-; methoxymethyl-carbamoyl-; and the like.
  • Halogen or halo refers to fluorine, chlorine, bromine or iodine. Fluorine, chlorine and bromine are preferred. Dihaloaryl-, dihaloalkyl-, trihaloaryl etc. refer to aryl and alkyl substituted with the designated plurality of halogens (here, 2, 2 and 3, respectively), but not necessarily a plurality of the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl-.
  • Heterocyclyl means a cycloalkyl or aryl residue in which one to foul of the carbons is replaced by a heteroatom such as oxygen, nitrogen or sulfur. Examples of heterocycles that fall within the scope of the invention include azetidinyl-, imidazolinyl-, pyrrolidinyl-, pyrazolyl-, pyrrolyl-, indolyl-, quinolinyl-, isoquinolinyl-, tetrahydroisoquinolinyl-, benzofuranyl-, benzodioxanyl-, benzodioxyl (commonly referred to as methylenedioxyphenyl-, when occurring as a substituent), tetrazolyl-, morpholinyl-, thiazolyl-, pyridinyl-, pyridazinyl-, piperidinyl-, pyrimidinyl-, thienyl-, furanyl-, oxazolyl-, oxazolinyl-, isoxazolyl-, dioxanyl-, tetrahydrofuranyl and the like. “N-heterocyclyl” refers to a nitrogen-containing heterocycle. The term heterocyclyl encompasses heteroaryl-, which is a subset of heterocyclyl-. Examples of N-heterocyclyl residues include azetidinyl-, 4-morpholinyl-, 4-thiomorpholinyl-, 1-piperidinyl-, 1-pyrrolidinyl-, 3-thiazolidinyl-, piperazinyl and 4-(3,4-dihydrobenzoxazinyl). Examples of substituted heterocyclyl include 4-methyl-1-piperazinyl and 4-benzyl-1-piperidinyl-.
  • A leaving group or atom is any group or atom that will, under the reaction conditions, cleave from the stating material, thus promoting reaction at a specified site. Suitable examples of such groups unless otherwise specified are halogen atoms, mesyloxy, p-nitrobenzensulphonyloxy and tosyloxy groups.
  • Optional or optionally means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstances occurs and instances in which it does not. For example, “optionally substituted alkyl” includes “alkyl” and “substituted alkyl” as defined herein. It wilt be understood by those skilled in the art with respect to any group containing one or more substituents that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical and/or synthetically non-feasible and/or inherently unstable.
  • Substituted alkoxy refers to alkoxy wherein the alkyl constituent is substituted (i.e., —O-(substituted alkyl)). One suitable substituted alkoxy group is “polyalkoxy” or —O-(optionally substituted alkylene)-(optionally substituted alkoxy), and includes groups such as —OCH2CH2OCH3, and residues of glycol ethers such as polyethyleneglycol, and —O(CH2CH2O)xCH3, where x is an integer of about 2-20, preferably about 2-10, and more preferably about 2-5. Another suitable substituted alkoxy group is hydroxyalkoxy or —OCH2(CH2)yOH, where y is an integer of about 1-10, preferably about 1-4.
  • Substituted- alkyl-, aryl-, and heteroaryl- refer respectively to alkyl-, aryl-, and heteroaryl wherein one or more (up to about 5, preferably up to about 3) hydrogen atoms are replaced by a substituent independently selected from the group: —Ra, —ORb, —O(C1-C2 alkyl)O— (as an aryl substituent), —SRb, —NRbRc, —NRcC(NRb)(NRbRc) (i.e, guanidine), —NRcCRbNRbRc, —CNRcNRbRc, halogen, cyano, nitro, —CORb, —CO2Rb, —CONRbRc, —OCORb, —OCO2Ra, —OCONRbRc, —NRcCORb, —NRcCORb, —NRcCO2Ra, —NRcCONRbRc, —CO2Rb, —CONRbRc, —NRcCORb, —SORa, —SO2Ra, —SO2NRbRc, and —NRcSO2Ra,
  • where Ra is an optionally substituted C1-C6 alkyl-, aryl-, heteroaryl-, aryl-C1-C4 alkyl-, or heteroaryl-C1-C4 alkyl- group,
  • Rb is H or optionally substituted C1-C6 alkyl-, aryl-, heteroaryl-, aryl-C1-C4 alkyl-, or heteroaryl-C1-C4 alkyl- group;
  • Rc is hydrogen, alkyl-; aryl- or heteroaryl-; and where each optionally substituted Ra group and Rb group is independently unsubstituted or substituted with one or more substituents independently selected from C1-C4 alkyl-, aryl-, heterocyclyl-, aryl-C1-C4 alkyl-, heteroaryl-C1-C4 alkyl-, C1-C4 haloalkyl-, —OC1-C4 alkyl-, —OC1-C4 alkylphenyl-, —C1-C4 alkyl-OH, —OC1-C4 haloalkyl-, halogen, —OH, —NH2, —C1-C4 alkyl-NH2, —N(C1-C4 alkyl)(C1-C4 alkyl), —NH(C1-C4 alkyl), —N(C1-C4 alkyl)(C1-C4 alkylphenyl), —NH(C1-C4 alkylphenyl), cyano, nitro, oxo (as a substituent for heteroaryl), —CO2H, —C(O)OC1-C4 alkyl-, —CON(C1-C4 alkyl)(C1-C4 alkyl), —CONH(C1-C4 alkyl), —CONH2, —NHC(O)(C1-C4 alkyl), —NHC(O)(phenyl), —N(C1-C4 alkyl)C(O)(C1-C4 alkyl), —N(C1-C4 alkyl)C(O)(phenyl), —C(O)C1-C4 alkyl-, —C(O)C1-C4 phenyl-, —C(O)C1-C4 haloalkyl-, —OC(O)C1-C4 alkyl-, —SO2(C1-C4 alkyl), —SO2(phenyl), —SO2(C1-C4 haloalkyl), —SO2NH2, —SO2NH(C1-C4 alkyl), —SO2NH(phenyl), —NHSO2(C1-C4 alkyl), —NHSO2(phenyl), and —NHSO2(C1-C4 haloalkyl).
  • Sulfanyl refers to the groups: —S-(optionally substituted alkyl), —S-(optionally substituted aryl), —S-(optionally substituted heteroaryl), and —S-(optionally substituted heterocyclyl).
  • Sulfinyl refers to the groups: —S(O)—H, —S(O)-(optionally substituted alkyl), —S(O)-optionally substituted aryl), —S(O)-(optionally substituted heteroaryl), —S(O)-(optionally substituted heterocyclyl); and —S(O)-(optionally substituted amino).
  • Sulfonyl refers to the groups: —S(O2)—H, —S(O2)-(optionally substituted alkyl), —S(O2)-optionally substituted aryl), —S(O2)-(optionally substituted heteroaryl), —S(O2)-(optionally substituted heterocyclyl), —S(O2)-(optionally substituted alkoxy), —S(O2)-optionally substituted aryloxy), —S(O2)-(optionally substituted heteroaryloxy), —S(O2)-(optionally substituted heterocyclyloxy); and —S(O2)-(optionally substituted amino).
  • Pharmaceutically acceptable salts refers to those salts that retain the biological effectiveness of the free compound and that are not biologically undesirable or unsuitable for pharmaceutical use, formed with a suitable acid or base, and includes pharmaceutically acceptable acid addition salts and base addition salts. Pharmaceutically acceptable acid addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and those derived from organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
  • Pharmaceutically acceptable base addition salts include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particular embodiments are the ammonium, potassium, sodium, calcium, and magnesium salts. Base addition salts also include those derived from pharmaceutically acceptable organic non-toxic bases, including salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.
  • Protecting group has the meaning conventionally associated with it in organic synthesis, i.e. a group that selectively blocks one or more reactive sites in a multifunctional compound such that a chemical reaction can be carried out selectively on another unprotected reactive site and such that the group can readily be removed after the selective reaction is complete. A variety of protecting groups are disclosed, for example, in T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, Third Edition, John Wiley & Sons, New York (1999), which is incorporated herein by reference in its entirety. For example, a hydroxy protected form is where at least one of the hydroxyl groups present in a compound is protected with a hydroxy protecting group. Likewise, amities and other reactive groups may similarly be protected.
  • Solvate refers to the compound formed by the interaction of a solvent and a compound of Formula I or salt thereof, and as will be understood by those skilled in the art, is the compound or salt with which a solvent is incorporated, for example, into the crystal structure. Suitable solvates of the compounds of the Formula I or a salt thereof are those formed with a pharmaceutically acceptable solvent, including hydrates (i.e., wherein the solvent is water).
  • Many of the compounds described herein contain one or more asymmetric centers (e.g. the carbon to which R2 and R2′ are attached where R2 differs from R2′) and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)— or (S)—. The present invention is meant to include all such possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures. Optically active (R)— and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms and rotational isomers are also intended to be included.
  • When desired, the R— and S-isomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallization; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where the desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step may be required to liberate the desired enantiomeric form. Alternatively, specific enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
  • Compounds of the Present Invention
  • The present invention is directed to a class of novel compounds, that can be described as isoquinolone derivatives, that are inhibitors of one or more mitotic kinesins. By inhibiting mitotic kinesins, but not other kinesins (e.g., transport kinesins), specific inhibition of cellular proliferation is accomplished. While not intending to be bound by any theory, the present invention capitalizes on the finding that perturbation of mitotic kinesin function causes malformation or dysfunction of mitotic spindles, frequently resulting in cell cycle arrest and cell death. According to one embodiment of the invention, the compounds described herein inhibit the mitotic kinesin, KSP, particularly human KSP. In another embodiment, the compounds inhibit the mitotic kinesin, KSP, as well as modulating one or more of the human mitotic kinesins selected from the group consisting of HSET (see, U.S. Pat. No. 6,361,993, which is incorporated herein by reference); MCAK (see, U.S. Pat. No. 6,331,424, which is incorporated herein by reference); CENP-E (see, PCT Publication No. WO 99/13061, which is incorporated herein by reference); Kif4 (see, U.S. Pat. No. 6,440,684, which is incorporated herein by reference); MKLP1 (see, U.S. Pat. No. 6,448,025, which is incorporated herein by reference); Kif15 (see, U.S. Pat. No. 6,355,466, which is incorporated herein by reference); Kid (see, U.S. Pat. No. 6,387,644, which is incorporated herein by reference); Mpp1, CMKrp, Kin1-3 (see, U.S. Pat. No. 6,461,855, which is incorporated herein by reference); Kip3a (see, PCT Publication No. WO 01/96593, which is incorporated herein by reference); Kip3d (see, U.S. Pat. No. 6,492,151, which is incorporated herein by reference); and RabK6.
  • The methods of inhibiting a mitotic kinesin comprise contacting an inhibitor of the invention with a kinesin, particularly a human kinesin, more particularly, human KSP or fragments and variants thereof. The inhibition can be of the ATP hydrolysis activity of the KSP kinesin and/or the mitotic spindle formation activity, such that the mitotic spindles are disrupted. Meiotic spindles may also be disrupted.
  • The present invention provides inhibitors of mitotic kinesins, in particular KSP and especially human KSP, for the treatment of disorders associated with cell proliferation. The compounds, compositions and methods described herein can differ in their selectivity and are used to treat diseases of cellular proliferation, including, but not limited to cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders, fungal disorders and inflammation.
  • Accordingly, the present invention relates to methods employing compounds represented by Formula I:
    Figure US20060019988A1-20060126-C00002
    wherein,
  • R1 is chosen from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl;
  • R2 and R2′ are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; or R2 and R2′ taken together form an optionally substituted 3- to 7-membered ring;
  • R12 is selected from the group consisting of optionally substituted imidazolyl, optionally substituted imidazolinyl, —NHR4; —N(R4)(COR3); —N(R4)(SO2R3a); and —N(R4)(CH2R3b);
  • R3 is chosen from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, R15O— and R17—NH—;
  • R3a is chosen from optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, and R17—NH—;
  • R3b is chosen from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl;
  • R4 is chosen from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, and optionally substituted heteroaralkyl;
  • R5, R6, R7 and R8 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted alkoxy, halogen, hydroxyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, optionally substituted aryl and optionally substituted heteroaryl;
  • R15 is chosen from optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl; and
  • R17 is chosen from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl;
  • including single stereoisomers and mixtures of stereoisomers;
  • a pharmaceutically acceptable salt of a compound of Formula I;
  • a pharmaceutically acceptable solvate of a compound of Formula I;
  • or a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt of a compound of Formula I. In a particular embodiment, the stereogenic center to which R2 and R2′ are attached is of the R configuration.
  • Nomenclature
  • The compounds of Formula I can be named and numbered in the manner described below (e.g., using AutoNom version 2.1 in ISIS-DRAW or ChemDraw). For example, the compound:
    Figure US20060019988A1-20060126-C00003
    i.e., the compound according to Formula I where R1 is benzyl-, R2 is propyl (or i-propyl), R2′ is hydrogen; R12 is substituted imidazolinyl wherein R10 and R10′ are methyl, R11 and R11′ are hydrogen and R14 is p-tolyl; R5, R6, and R8 are hydrogen; and R7 is chloro can be named 2-Benzyl-6-chloro-3-[1-(4,4-dimethyl-2-p-tolyl-4,5-dihydro-imidazol-1-yl)-2-methyl-propyl]-2H-isoquinolin-1-one.
  • Likewise, the compound:
    Figure US20060019988A1-20060126-C00004
    i.e., the compound according to Formula I where R1 is benzyl-, R2 is propyl (or i-propyl), R2′ is hydrogen; R12 is —N(R4)(COR3) wherein R4 is 3-aminopropyl- and R3 is p-tolyl; R5, R6, and R8 are hydrogen; and R7 is chloro can be named N-(3-Amino-propyl)-N-[1-(2-benzyl-6-chloro-1-oxo-1,2-dihydro-isoquinolin-3-yl)-2-methyl-propyl]-4-methyl-benzamide.
    Synthetic Reaction Parameters
  • The compounds of Formula I can be prepared by following the procedures described with reference to the Reaction Schemes below.
  • Unless specified otherwise, the terms “solvent”, “inert organic solvent” or “inert solvent” mean a solvent inert under the conditions of the reaction being described in conjunction therewith [including, for example, benzene, toluene, acetonitrile, tetrahydrofuran (“THF”), dimethylformamide (“DMF”), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, pyridine and the like]. Unless specified to the contrary, the solvents used in the reactions of the present invention are inert organic solvents.
  • The term “q.s.” means adding a quantity sufficient to achieve a stated function, e.g., to bring a solution to the desired volume (i.e., 100%).
  • In general, esters of carboxylic acids may be prepared by conventional esterification procedures, for example alkyl esters may be prepared by treating the required carboxylic acid with the appropriate alkanol, generally under acidic conditions. Likewise, amides may be prepared using conventional amidation procedures, for example amides may be prepared by treating an activated carboxylic acid with the appropriate amine. Alternatively, a lower-alkyl ester such as a methyl ester of the acid may be treated with an amine to provide the required amide, optionally in presence of trimethylalluminium following the procedure described in Tetrahedron Lett. 48, 4171-4173, (1977). Carboxyl groups may be protected as alkyl esters, for example methyl esters, which esters may be prepared and removed using conventional procedures, one convenient method for converting carbomethoxy to carboxyl is to use aqueous lithium hydroxide.
  • The salts and solvates of the compounds mentioned herein may as required be produced by methods conventional in the art. For example, if an inventive compound is an acid, a desired base addition salt can be prepared by treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary); an alkali metal or alkaline earth metal hydroxide; or the like. Illustrative examples of suitable salts include organic salts derived from amino acids such as glycine and arginine; ammonia; primary, secondary, and tertiary amines; such as ethylenediamine, and cyclic amines, such as cyclohexylamine, piperidine, morpholine, and piperazine; as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
  • If a compound is a base, a desired acid addition salt may be prepared by any suitable method known in the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, (glycolic acid, salicylic acid, pyranosidyl acid, such as (glucuronic acid or galacturonic acid, alpha-hydroxy acid, such as citric acid or tartaric acid, amino acid, such as aspartic acid or glutamic acid, aromatic acid, such as benzoic acid or cinnanic acid, sulfonic acid, such as p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, or the like.
  • Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had by reference to the examples hereinbelow. However, other equivalent separation or isolation procedures can, of course, also be used.
    • Synthesis of the Compounds of Formula I
  • The compounds of Formula I can be prepared by following the procedures described in U.S. patent application Ser. No. 10/366,828 and corresponding PCT Application No. US03/04713; and PCT Publication Nos. WO 01/30768 and WO 01/98278, each of which is incorporated herein by reference for all purposes, and with reference to the Reaction Schemes below.
  • Brief Description of Reaction Schemes
  • Reaction Scheme 1 illustrates a synthesis of an intermediate (i.e., compounds of Formula 113) in the synthesis of compounds of Formula I.
  • Reaction Scheme 2 illustrates a synthesis of compounds of Formula I wherein R12 is —N(R4)(COR3) from compounds of Formula 113.
  • Reaction Scheme 3 shows a synthesis of compounds of Formula I wherein R12 is —N(R4)(SO2R3a) from compounds of Formula 203.
  • Reaction Scheme 4 shows a synthesis of compounds of Formula I wherein R12 is —N(R4)(CH2R3b) from compounds of Formula 203.
  • Reaction Scheme 5 shows a synthesis of compounds of Formula I wherein R12 is optionally substituted imidazolyl from compounds of Formula 113.
  • Reaction Scheme 6 shows a synthesis of compounds of Formula I wherein R12 is optionally substituted imidazolyl from compounds of Formula 113.
  • Reaction Scheme 7 shows a synthesis of compounds of Formula I wherein R12 is optionally substituted imidazolinyl from compounds of Formula 113.
  • Reaction Scheme 8 shows a synthesis of compounds of Formula I wherein R12 is optionally substituted imidazolinyl from compounds of Formula 705.
  • Reaction Scheme 9 shows a synthesis of compounds of Formula I wherein R12 is —N(R4)(COR3) and R3 is —OR15, from compounds of Formula 203.
  • Reaction Scheme 10 shows a synthesis of compounds of Formula I wherein R12 is —N(R4)(COR3) and R3 is —NHR17, from compounds of Formula 203.
  • Reaction Scheme 11 shows a synthesis of compounds of Formula I wherein R12 is optionally substituted imidazolyl.
  • Reaction Scheme 12 shows a synthesis of compounds of Formula I wherein R12 is optionally substituted imidazolinyl from compounds of Formula 113.
  • Starting Materials
  • The optionally substituted benzoic acids of Formula 101 and the other reactants are commercially available, e.g., from Aldrich Chemical Company, Milwaukee, Wis. or may be readily prepared by those skilled in the art using commonly employed synthetic methodology.
    Figure US20060019988A1-20060126-C00005
    Preparation of Compounds of Formula 103
  • Referring to Reaction Scheme 1, Step 1, an optionally substituted carboxylic acid of Formula 101 is protected with a suitable protecting group. For example, the following procedure is used to prepare esters of the carboxylic acid. A solution of a compound of Formula 101 and thionyl chloride in a polar aprotic solvent (such as DMF) is warmed gently until the mixture becomes homogeneous. The solution is concentrated. A lower alkanol, such as methanol, is then added. The corresponding, optionally substituted compound of Formula 103 is isolated and purified.
  • Preparation of Compounds of Formula 105
  • Referring to Reaction Scheme 1, Step 2, a compound of Formula 103 is coupled to a compound of Formula 104. A variety of reaction conditions can be used to effect this coupling, e.g., Sonogashira coupling conditions using a palladium catalyst such as (diphenylphosphineferrocenyl)dichloropalladium or tris(dibenzylidenacetone)-dipalladium; a base such as cesium carbonate or triethylamine; and ligands such as triphenylarsine or triphenylphosphine; Stille conditions using a palladium catalyst such as tris(dibenzylidinacetone)-dipalladium; lithium chloride; and triphenylarsine; or Suzuki coupling conditions wherein the compound of Formula 104 is treated with a borane such as catechol borane or 9-borabicyclo[3.3.1]nonane and the two fragments are coupled using a palladium catalyst such as those described above, a base such as cesium carbonate, and triphenylarsine.
  • According to one embodiment, a mixture of a compound of Formula 103; a slight excess (preferably about 1.1 equivalents) of an acetylenic compound of Formula 104; a palladium catalyst such as dichlorobis(triphenylphosphine)palladium(II) and preferably about 0.025 equivalents of the catalyst; and cuprous iodide in a base such as triethylamine is heated at about 50° C. The corresponding, optionally substituted compound of Formula 105 is isolated and purified.
  • Preparation of Compounds of Formula 107
  • Referring to Reaction Scheme 1, Step 3, the protecting group is then removed from the carboxylic acid. When the protecting group is a lower alkyl ester, it can be removed by treatment with aqueous alcoholic base at an elevated temperature. For example, methyl esters can be converted to the corresponding carboxylic acid by treatment of the ester with potassium hydroxide in a 1:1:1 solution of methanol, THF, and alcohol at about 50° C. for 30 minutes. The corresponding, optionally substituted compound of Formula 107 is isolated and used without further purification.
  • Preparation of Compounds of Formula 109
  • Referring to Reaction Scheme 1, Step 4, bis(acetonitrile)dichloropalladium (about 0.050 equivalents) is added to a solution of a compound of Formula 107 and a base, such as triethylamine, in a nonpolar, aprotic solvent such as THF. The solution is maintained at an elevated temperature, preferably about 50° C. The corresponding, optionally substituted isochromen-1-one of Formula 109 is isolated and purified.
  • Preparation of Compounds of Formula 111
  • Referring to Reaction Scheme 1, Step 5, a solution of isochromen-1-one of Formula 109 and an excess (preferably about 3 equivalents) of a primary amine of formula R1NH2 in a nonpolar solvent such as toluene is heated at reflux, preferably about 140° C. The resulting amide is isolated and dissolved in a polar, protic solvent such as methanol. Aqueous acid, preferably about 5% aqueous hydrochloric acid is added to the solution which is then heated to about 50° C. Additional aqueous alcholic acid may be added if required to complete the reaction. The corresponding, optionally substituted 2H-isoquinolin-1-one of Formula 111 is isolated and purified.
  • Preparation of Compounds of Formula 113
  • Referring to Reaction Scheme 1, Step 6, the protecting group is removed from the primary amine. In a preferred embodiment, the protecting group is Boc and its removal can be accomplished through treatment with aqueous TFA at room temperature. The product, a compound of Formula 113 is isolated and can be used without further purification.
  • In certain compounds of the invention, particular stereoconfiguration can be preferred for the R2 substituent, such as the (R) isomer, which can be obtained. An amine of Formula 113 is dissolved in an inert organic solvent (such as IPA) and warmed to 60° C. In a separate vessel, a resolving, agent (such as dibenzoyl-D-tartaric acid) is dissolved, preferably in the same warm solvent, and then quickly added (with agitation) to the warm amine solution. The reaction mixture is left to crystallize by cooling to room temperature over 16 hours under continuing agitation. The desired isomer, e.g., the (R) isomer is isolated and purified in the usual manner.
  • For the sake of brevity in the remaining description of the synthesis of compounds of Formula I, it should be understood that either single isomer or a mixture of isomers may be employed to give the corresponding product.
    Figure US20060019988A1-20060126-C00006
    Preparation of Formula 203
  • Referring to Reaction Scheme 2, Step 1, to a solution of a compound of Formula 113 is added successively a slight excess (preferably about 1.2 equivalents) of an aldehyde comprising R4′ (i.e., a compound having the formula R4′CHO where R4′CH2— is equivalent to R4 and R4 is as described above or is a protected precursor to such a substituent, e.g., (3-oxo-propyl)-carbamic acid tert-butyl ester) and a reducing agent such as sodium triacetoxyborohydride. The resulting mixture is stirred for several hours. The product, a compound of Formula 203 is isolated and purified.
  • Preparation of Formula 205
  • Referring to Reaction Scheme 2, Step 2, to a solution of a compound of Formula 203 and an amine base such as diisopropylethylamine in a nonpolar, aprotic solvent such as dichloromethane is added an R3 acyl chloride (such as Cl—C(O)—R3 where R3 is as described above). The resulting solution is stirred under nitrogen at room temperature for several hours. The product, a compound of Formula 205 is isolated and purified.
  • Preparation of Formula 207
  • Optionally, any protecting groups on compounds of Formula 205 are then removed. For example, if R4 comprises a protected amine wherein the protecting group is a Boc group, the Boc group can be removed by treatment of the compound of Formula 205 with an acid such as trifluoroacetic acid in a nonpolar, aprotic solvent such as dichloromethane, while maintaining the reaction at about room temperature. The reaction is monitored e.g., by TLC. Upon completion, the product, a compound of Formula 207 is isolated and purified.
    Figure US20060019988A1-20060126-C00007
  • Referring to Reaction Scheme 3, to a solution of a compound of Formula 203 and an amine base such as diisopropylethylamine in a nonpolar, aprotic solvent such as dichloromethane is added a compound having the formula Cl—S(O)2—R3a or O—(S(O)2—R3a)2 where R3a is as described above. The resulting solution is stirred under nitrogen at room temperature for several hours. The product, a compound of Formula 303 is isolated and purified.
    Figure US20060019988A1-20060126-C00008
  • Referring to Reaction Scheme 4, to a solution of a compound of Formula 203 and an amine base such as diisopropylethylamine in a nonpolar, aprotic solvent such as dichloromethane is added a compound having the formula Cl—CH2—R3b where R3b is as described above. The resulting solution is stirred under nitrogen at room temperature or with heat for several hours. The product, a compound of Formula 403 is isolated and purified.
    Figure US20060019988A1-20060126-C00009
    Preparation of Formula 503
  • Referring to Reaction Scheme 5, Step 1, to an optionally substituted compound of Formula 113 dissolved in a polar, aprotic solvent (such as DMF) in the presence of a base (such as potassium carbonate) is added one equivalent of an optionally substituted suitably protected aldehyde wherein such aldehyde further comprises a leaving group, preferably, a halide. The solution is heated at reflux, monitoring completion of the reaction (e.g., by TLC). The reaction mixture is cooled and the corresponding, optionally substituted compound of Formula 503 is isolated and purified.
  • Preparation of Formula 505
  • Referring to Reaction Scheme 5, Step 2, to an optionally substituted compound of Formula 503 in an inert solvent (such as dichloromethane) in the presence of about 1.5 molar equivalents of an amine base (such as triethylamine) is added about 1.5 molar equivalents of an R9 acid chloride, such as, Cl—C(O)—R9, where R9 is as described above. The reaction takes place, with stirring, at room temperature over a period of 4 to 24 hours. Completion is monitored, e.g., by TLC. The corresponding compound of Formula 505 is isolated and purified.
  • Preparation of Formula 507
  • Referring to Reaction Scheme 5, Step 3, a solution of a compound of Formula 505 and an excess of ammonium acetate in acetic acid is heated at reflux for 1-4 hours. Completion is monitored, e.g., by TLC. The corresponding compound of Formula 507 is isolated and purified.
    Figure US20060019988A1-20060126-C00010
    Preparation of Formula 603
  • Referring to Reaction Scheme 6, Step 1, a suspension of a compound of Formula 113, an alpha-haloketone reagent of the Formula R13′(CO)CH2X wherein X is a leaving group (such as a halide) and R13′ is as described herein, and about an equivalent of a base, such as potassium carbonate in a polar, aprotic solvent such as DMF is stirred at room temperature. The reaction is diluted with water and the resulting solid, a compound of Formula 603, is used in the subsequent step without further purification.
  • Preparation of Formula 605
  • Referring to Reaction Scheme 6, Step 2, a solution of the compound of Formula 603, about an equivalent of an amine base, such as triethylamine and about an equivalent of an acid chloride (such as a compound of Formula R9—COCl) in an organic solvent such as methylene chloride is stirred at room temperature for several hours. Completion is monitored, e.g., by TLC. The corresponding compound of Formula 605 is isolated and purified.
  • Preparation of Formula 607
  • Referring to Reaction Scheme 6, Step 3, a solution of a compound of Formula 605 and an excess of ammonium acetate in acetic acid is heated at reflux using a Dean-Stark trap and condenser. Completion is monitored, e.g., by TLC. The corresponding compound of Formula 607 is isolated and purified.
  • Preparation of Formula 609
  • Optionally, in the event that group R13′ comprises a functionality bearing a protecting group, the protecting group is removed. Thus, if R13′ further comprises an amine bearing a Pht group, the protecting group is removed as shown in Reaction Scheme 6, Step 4. A solution of a compound of Formula 607 and an excess of anhydrous hydrazine in a polar, protic solvent such as ethanol is heated at reflux. The reaction is cooled to about 5° C. and any precipitate is filtered off. The filtrate is concentrated in vacuo and purified to yield a compound of Formula 609.
    Figure US20060019988A1-20060126-C00011
    Preparation of Formula 703
  • Referring to Reaction Scheme 7, Step 1, reductive amination of amines of Formula 113 (prepared as described in WO 0130768) with an optionally substituted, aldehyde-containing carbamic acid ester (Seki et. al. Chem. Pharm. Bull. 1996, 44, 2061) gives urethane intermediates. Removal of the Boc protecting group furnishes an amine of Formula 705.
  • More specifically, to a solution of a compound of Formula 113 and an equivalent of a suitably protected aldehyde (Seki et. al. Chem. Pharm. Bull. 1996, 44, 2061) in dichloromethane is added a slight excess of a reducing agent, such as sodium triacetoxyborohydride. The resultant cloudy mixture is maintained at ambient temperature. Completion is monitored, e.g., by TLC. The corresponding compound of Formula 703 is isolated and used in the subsequent step without purification.
  • Preparation of Formula 705
  • Referring to Reaction Scheme 7, Step 2, the amine protecting group, PG, is the removed. For example, when PG is Boc, to a solution of a compound of Formula 703 in a nonpolar, aprotic solvent such as dichloromethane is added a strong acid such as trifluoroacetic acid. The resultant solution is maintained at ambient temperature overnight and concentrated under reduced pressure. The residue is isolated to give a compound of Formula 705 which was used in the subsequent step without purification.
  • Preparation of Formula 707
  • Referring to Reaction Scheme 7, Step 3, to a solution of a compound of Formula 705 in a-nonpolar, aprotic solvent such as dichloromethane is added an excess, preferably about two equivalents of an amine base such as triethylamine, followed by about an equivalent or slight excess of an acid chloride of the formula R14COCl. The resultant solution is stirred at ambient temperature for about 3 hours. Completion is monitored, e.g., by TLC. The corresponding compound of Formula 707 is isolated and purified.
  • Preparation of Formula 709
  • Referring, to Reaction Scheme 7, Step 4, a solution of a compound of Formula 707 in an excess of phosphorus oxychloride is heated at reflux. After 8 hours, the reaction mixture is allowed to cool to ambient temperature and concentrated under reduced pressure. The corresponding compound of Formula 709 is isolated and purified.
    Figure US20060019988A1-20060126-C00012
    Preparation of Formula 709
  • As an alternative to Steps 3 and 4 of Reaction Scheme 7, acylation of primary amines of Formula 705, followed by acetic acid mediated cyclization, can proceed without isolation of the intermediate amides to provide the target compound of Formula 709. This is route is shown in Reaction Scheme 8.
  • More specifically, to a solution of a compound of Formula 705 in a nonpolar, aprotic solvent such as dichloromethane is added an excess, preferably about two equivalents of an amine base, such as triethylamine, followed by about an equivalent of an acid chloride of formula R14COCl. The resultant solution is stirred at ambient temperature for 2 hours, then evaporated under reduced pressure. The resultant solid is treated with glacial acetic acid, then the resultant suspension is heated at reflux for about 48 hours. The reaction is cooled to ambient temperature then evaporated under reduced pressure. The corresponding compound of Formula 709 is isolated and purified.
    Figure US20060019988A1-20060126-C00013
  • Referring to Reaction Scheme 9, a compound of Formula 203 is reacted with a slight excess of a compound of the formula R15O(CO)Cl in the presence of a base such as triethylamine in a nonpolar, aprotic solvent such as dichloromethane. The product, a compound of Formula 903 is isolated and purified.
    Figure US20060019988A1-20060126-C00014
  • Referring to Reaction Scheme 10, a compound of Formula 203 is treated with a slight excess of an isocyanate R17—N═C═O in the presence of a base, such as triethylamine, in a nonpolar, aprotic solvent, such as dichloromethane. The product, a compound of Formula 1003, is isolated and purified.
    Figure US20060019988A1-20060126-C00015
    Preparation of Compounds of Formula 1103
  • Referring to Reaction Scheme 11, to a solution of a compound of Formula 1101 in a nonpolar, aprotic solvent such as DMF are added a base such as triethylamine and an excess (preferably, about 1.5 equivalents) of imidazole followed by about an equivalent of tetrabutylammonium iodide. The resultant solution is heated to about 90° C., stirred for about 18 h and allowed to cool to room temperature. The product, a compound of Formula 1103, is isolated and purified.
    Figure US20060019988A1-20060126-C00016
    Preparation of Compounds of Formula 1203
  • Referring to Reaction Scheme 12, Step 1, to a solution of a compound of Formula 113 and an excess of an optionally substituted, aldehyde-containing, carbamic acid ester such as ((S)-4-benzyloxycarbonylamino-1-formyl-butyl)-carbamic acid tert-butyl ester) in a nonpolar, aprotic solvent such as CH2Cl2 is added sodium triacetoxyborohydride. The mixture is strirred overnight. The product, a compound of Formula 1203, is isolated and purified.
  • Preparation of Compounds of Formula 1205
  • Referring to Reaction Scheme 12, Step 2, to a solution of a compound of Formula 1203 in a nonpolar, aprotic solvent such as toluene is added a base such as triethylamine followed by dropwise addition of an excess of an acid chloride of the formula R14—COCl. The reaction mixture is heated to about 80° C. for about 18 h, then at reflux for about 4 h. The product, a compound of Formula 1205, is isolated and purified.
  • Preparation of Compounds of Formula 1207
  • Referring to Reaction Scheme 12, Step 3, a solution of a compound of Formula 1205 in a solvent such as CH2Cl2/TFA (preferably, about 4:1 CH2Cl2/TFA) is stirred at room temperature. The reaction mixture is concentrated under reduced pressure and the residue is diluted with a nonpolar, aprotic solvent such as CH2Cl2 and washed with aqueous base. The aqueous layer is extracted with a nonpolar, aprotic solvent such as CH2Cl2 and the combined extracts are dried, filtered and concentrated under reduced pressure. The residue is diluted with a nonpolar, aprotic solvent such as THF and aqueous base (preferably, saturated aqueous NaHCO3). The mixture is stirred at room temperature for 10 days. The product, a compound of Formula 1207, is isolated and purified.
    • Particular Processes and Last Steps
  • A compound of Formula 203:
    Figure US20060019988A1-20060126-C00017
    (where R4 is optionally protected) is contacted with a slight molar excess of an R3 chloride [such as, Cl—C(O)—R3, Cl—S(O)2—R3a, Cl—CH2—R3b, Cl—C(O)—O—R15 and Cl—S(O)2—NH—R3a] or an isocyanate (such as O═C═N—R17) or an anhydride (such as O[C(O)R15]2 or O[S(O)2R3a]2) to give the corresponding optionally protected compound of Formula I.
  • A compound of Formula 505, 605, 705, or 707 is optionally cyclized by acid-mediated cyclization.
  • A racemic mixture of isomers of a compound of Formula I is optionally placed on a chromatography column and separated into (R)— and (S)-enantiomers.
  • A compound of Formula I is optionally contacted with a pharmaceutically acceptable acid or base to form the corresponding acid or base addition salt.
  • A pharmaceutically acceptable acid addition salt of a compound of Formula I is optionally contacted with a base to form the corresponding free base of Formula I.
  • A pharmaceutically acceptable base addition salt of a compound of Formula I is optionally contacted with an acid to form tile corresponding free acid of Formula I.
    • Particular Embodiments of Compounds of the Invention
  • R1
  • When considering the compounds of Formula I, in one embodiment, R1 is selected from hydrogen, optionally substituted C1-C8 alkyl-, optionally substituted aryl-, optionally substituted heteroaryl-, optionally substituted aryl-C1-C4-alkyl-, and optionally substituted heteroaryl-C1-C4-alkyl- (more particularly optionally substituted aryl and optionally substituted aryl-C1-C4-alkyl-). In a more particular embodiment R1 is selected from hydrogen, optionally substituted C1-C4 alkyl-, optionally substituted phenyl-C1-C4-alkyl-, optionally substituted naphthalenylmethyl-, optionally substituted phenyl-, and naphthyl-. Even more particularly, R1 is optionally substituted phenyl-C1-C4-alkyl-, optionally substituted heteroaryl-C1-C4-alkyl-, or naphthalenylmethyl-.
  • Yet more particularly, R1 is naphthyl-, phenyl-, bromophenyl-, chlorophenyl-, methoxyphenyl-, ethoxyphenyl-, tolyl-, dimethylphenyl-, chorofluorophenyl-, methylchlorophenyl-, ethylphenyl-, phenethyl-, benzyl-, chlorobenzyl-, methylbenzyl-, methoxybenzyl-, cyanobenzyl-, hydroxybenzyl-, dichlorobenzyl-, dimethoxybenzyl-, or naphthalenylmethyl-. More suitably, R1 is benzyl-, cyanobenzyl-, methoxybenzyl-, or naphthalenylmethyl-. Most particularly, R1 is benzyl-.
  • R2 and R2′
  • When considering the compounds of Formula I and as will be appreciated by those skilled in the art, the compounds described herein possess a potentially chiral center at the carbon to which R2 and R2′ are attached. The R2 and R2′ groups may be the same or different; if different, the compound is chiral (i.e., has a stereogenic center). When R2 and R2′ are different, in particular embodiments R2′ is hydrogen and R2 is other than hydrogen. The invention contemplates the use of pure enantiomers and mixtures of enantiomers, including racemic mixtures, although the use of a substantially optically pure enantiomer will generally be preferred. The term “substantially pure” means having at least about 95% chemical purity with no single impurity greater than about 1%. The term “substantially optically pure” or “enantiomerically pure” means having at least about 97.5% enantiomeric excess. In a a particular embodiment, the stereogtenic center to which R2 and R2′ are attached is of the R configuration.
  • When considering the compounds of Formula I, in one embodiment, R2 and R2′ are independently chosen from hydrogen, optionally substituted alkyl-, optionally substituted alkoxy, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, and optionally substituted heteroaralkyl-.
  • In another embodiment, R2 and R2′ taken together form a 3- to 7-membered ring which may optionally be substituted one or more of the following groups: hydroxyl, halogen (particularly chloro and fluoro), optionally substituted C1-C4 alkyl- (particularly methyl-), C1-C4 alkoxy (particularly methoxy), cyano, amino, substituted amino, or carbamyl-.
  • In one embodiment, R2 is optionally substituted C1-C4 alkyl-, and R2′ is hydrogen or optionally substituted C1-C4 alkyl-. More suitably, R2′ is hydrogen and R2 is optionally substituted C1-C4 alkyl-. In a most particular embodiment R2 is chosen from methyl-, ethyl-, propyl (particularly, c-propyl or i-propyl), butyl (particularly, t-butyl), methylthioethyl-, methylthiomethyl-, aminobutyl-, (CBZ)aminobutyl-, cyclohexylmethyl-, benzyloxymethyl-, methylsulfanylethyl-, methylsulfanylmethyl-, and hydroxymethyl-, and R2′ is hydrogen. Especially chosen embodiments are when R2′ is hydrogen and R2 is ethyl or propyl (particularly, c-propyl or i-propyl). Even more particularly, R2 is i-propyl. Yet more particularly, the stereogenic center to which R2 and R2′ is attached is of the R configuration.
  • In one embodiment, if either R2 or R2′ is hydrogen, then the other is not hydrogen. In another embodiment, both R2 and R2′ are hydrogen.
  • R5, R6, R7, and R8
  • In other embodiments R5, R6, R7, and R8 are independently chosen from hydrogen, hydroxyl, halogen (particularly chloro and fluoro), optionally substituted C1-C4 alkyl- (particularly methyl-), C1-C4 alkoxy (particularly methoxy), cyano, amino, substituted amino, or carbamyl-. More particularly, R5, R6, R7, and R8 are methoxy, methyl, trifluoromethyl, cyano, hydrogen or halo. In particular embodiments, R5 is hydrogen or halo; R6 is hydrogen, optionally substituted C1-C4 alkyl- (particularly, methyl-) or halo; R7 is hydrogen, halo, optionally substituted C1-C4 alkyl- (particularly, methyl- or trifluoromethyl-), C1-C4 alkoxy (particularly, methoxy), cyano, substituted amino, or carbamyl-; and R8 is hydrogen, C1-C4 alkyl- (particularly, methyl-), C1-C4 alkoxy (particularly, methoxy), hydroxy, or halo. Still more particularly are the compounds where only one of R5, R6, R7, and R8 is not hydrogen, especially R7. Another particular embodiment is drawn to the compounds where R7 and R8 are not hydrogen.
  • Compounds Wherein R12 is an Optionally Substituted Imidazolyl
  • When R12 is an optionally substituted imidazolyl-, in particular embodiments, R12 has the formula:
    Figure US20060019988A1-20060126-C00018
    wherein
  • R9 is chosen from hydrogen, optionally substituted C1-C8 alkyl-, optionally substituted aryl-, optionally substituted aryl-C1-C4-alkyl-, optionally substituted heteroaryl-C1-C4-alkyl-, optionally substituted aryl-C1-C4-alkoxy, optionally substituted heteroaryl-C1-C4-alkoxy, and optionally substituted heteroaryl-; and
  • R13 and R13′ are independently hydrogen, optionally substituted C1-C8 alkyl-, optionally substituted aryl-, or optionally substituted aryl-C1-C4-alkyl-.
  • According to one embodiment, R9 is lower-alkyl; phenyl substituted with optionally substituted C1-C4-alkyl-, C1-C4-alkoxy-, and/or halo; phenyl-; benzyl-; thiophenyl-; or thiophenyl- substituted with C1-C4-alkyl-, C1-C4-alkoxy-, and/or halo. More suitably, R9 is lower-alkyl; phenyl-; or phenyl- substituted with one or more of the following groups: methyl, methoxy, trifluoromethyl, or halo.
  • According to another embodiment, R13 is hydrogen and R13′ is substituted C1-C4 alkyl-. More suitably, R13 is hydrogen and R13′ is aminomethyl-, aminoethyl-, aminopropyl-, acetylamino-methyl-, acetylaminoethyl-, benzyloxycarbonylamino-methyl- or benzyloxycarbonylamino-ethyl-.
  • Compounds Wherein R12 is an Optionally Substituted Imidazolinyl
  • When R12 is an optionally substituted imidazolinyl, in one embodiment, R12 has the formula
    Figure US20060019988A1-20060126-C00019
    wherein,
  • R14 is chosen from hydrogen, optionally substituted C1-C8 alkyl-, optionally substituted aryl-, optionally substituted aryl-C1-C4-alkyl-, optionally substituted heteroaryl-, optionally substituted heteroaryl-C1-C4-alkyl-; and
  • R10, R10′, R11 and R11′ are independently chosen from hydrogen, optionally substituted C1-C8 alkyl-, optionally substituted aryl-, and optionally substituted aryl-C1-C4-alkyl-.
  • In one embodiment, R14 is lower-alkyl-; methylenedioxyphenyl-; phenyl-; phenyl substituted with optionally substituted C1-C4 alkyl-, C1-C4 alkoxy-, and/or halo; benzyl-; thienyl substituted with C1-C4 alkyl; benzyl; thiophenyl-; or thiophenyl- substituted with C1-C4-alkyl-, C1-C4-alkoxy-, and/or halo. More suitably, R14 is lower-alkyl; phenyl-; or phenyl- substituted with one or more of the following groups: methyl, methoxy, trifluoromethyl, or halo.
  • In one embodiment, R10, R10′, R11′, and R11 are independently hydrogen or optionally substituted C1-C4 alkyl-. More suitably, R11′ it and R11 are hydrogen.
  • Compounds Wherein R12 is —NHR4, —NR4(COR3), NR4(SO2R3a), or —NR4(CH2R3b) R4
  • In one embodiment, R4 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, and optionally substituted heterocyclyl-. More suitably, R4 is R16-alkylene-, and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, carboxy, guanidine, hydroxyl-, and N-heterocyclyl-.
  • In a more particular embodiment, R4 is selected from optionally substituted lower-alkyl-, optionally substituted cyclohexyl-; phenyl substituted with hydroxy, lower-alkoxy or lower-alkyl-; benzyl-; heteroarylmethyl-; heteroarylethyl-; and heteroarylpropyl-.
  • In a most particular embodiment, R4 is chosen from methyl-, ethyl-, propyl-, butyl-, cyclohexyl-, carboxyethyl-, carboxymethyl-, methoxyethyl-, hydroxyethyl-, hydroxypropyl-, dimethylaminoethyl-, dimethylaminopropyl-, diethylaminoethyl-, diethylaminopropyl-, aminopropyl-, methylaminopropyl-, 2,2-dimethyl-3-(dimethylamino)propyl-, 1-cyclohexyl-4-(diethylamino)butyl-, aminoethyl-, aminobutyl-, aminopentyl-, aminohexyl-, aminoethoxyethyl-, isopropylaminopropyl-, diisopropylaminoethyl-, 1-methyl-4-(diethylamino)butyl-, (t-Boc)aminopropyl-, hydroxyphenyl-, benzyl-, methoxyphenyl-, methylmethoxyphenyl-, dimethylphenyl-, tolyl-, ethylphenyl-, (oxopyrrolidinyl)propyl-, (methoxycarbonyl)ethyl-, benzylpiperidinyl-, pyridinylethyl-, pyridinylmethyl-, morpholinylethyl morpholinylpropyl-, piperidinyl-, azetidinylmethyl-, azetidinylethyl-, azetidinylpropyl-, pyrrolidinylmethyl-, pyrrolidinylethyl-, pyrrolidinylpropyl-, piperidinylmethyl-, piperidinylethyl-, imidazolylpropyl-, imidazolylethyl-, (ethylpyrrolidinyl)methyl-, (methylpyrrolidinyl)ethyl-, (methylpiperidinyl)propyl-, (methylpiperazinyl)propyl-, guanidino-methyl-, guanidino-ethyl-, guanidino-propyl-, furanylmethyl and indolylethyl- (most especially aminopropyl).
  • R3
  • When considering the compounds of Formula I, in a particular embodiment R3 is selected from hydrogen, optionally substituted alkyl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, optionally substituted heteroaryl-, optionally substituted aryl-, R15O— and R17—NH—, wherein R15 is chosen from optionally substituted alkyl and optionally substituted aryl and R17 is chosen from hydrogen, optionally substituted alkyl and optionally substituted aryl-.
  • In a more particular embodiment, when R3 is not R17NH— or R15O—, R3 is chosen from optionally substituted alkyl-; aryl- (including phenyl-, biphenyl-, and naphthyl-); substituted aryl- (including phenyl substituted with one or more cyano, halo, lower-alkyl-, lower-alkoxy, hydroxy-loweralkyl-, nitro, carboxy, methylenedioxy, trifluoromethoxy, or trifluoromethyl-); benzyl-; and optionally substituted heteroaryl-.
  • In a most particular embodiment, when R3 is not R17NH— or R15O—, R3 is chosen from ethyl-, propyl-, chloropropyl-, butoxy, heptyl-, butyl-, octyl-, tridecanyl-, (ethoxycarbonyl)ethyl-, dimethylaminoethyl-, dimethylaminomethyl-, phenyl-, naphthyl-, halophenyl-, polyhalophenyl-, cyanophenyl-, hydroxymethylphenyl-, halo(trifluoromethyl)phenyl-, chlorophenoxymethyl-, methoxyphenyl-, carboxyphenyl-, ethylphenyl-, tolyl-,hydroxymethylphenyl-; ethylphenyl-; biphenylyl-, methylenedioxyphenyl-, methylsulfonylphenyl-, methoxychlorophenyl-, chloronaphthlyl-, acetylphenyl-, methylhalophenyl-, trifluoromethylphenyl-, trifluoromethoxyphenyl-, butylphenyl-, pentylphenyl-, methylnitrophenyl-, phenoxymethyl-, dimethoxyphenyl-, phenylvinyl-, nitrochlorophenyl-, nitrophenyl-, dinitrophenyl-, bis(trifluoromethyl)phenyl-, benzyloxymethyl-, benzyl-, furanyl-, benzofuranyl-, pyridinyl-, pyridyl-, indolyl-, methylpyridinyl-, methylpyridyl-, (3-carbamoyl)pyridinyl-[nicotinamide], 3-carbamoyl-6-methylpyridinyl-, quinolinyl-, picolinyl-, pyrazolyl-, pyrazinyl-, methylpyrazinyl-, morpholinomethyl-, methylthiomethyl-, methoxymethyl-, imidazolyl-; isoxazolyl-, methyl-isoxazolyl-; benzothiadiazolyl-; methylenedioxyphenyl-, thienyl-, methylthienyl-, methyl-nicotinamidyl-; methyl-pyrazinyl; benzodioxolyl; and methyl-thiophenyl-.
  • More suitably, R3 is tolyl-, halophenyl-, halomethylphenyl-, hydroxymethylphenyl-, methylenedioxyphenyl-, formylphenyl or cyanophenyl-.
  • In another particular embodiment, when R3 is R17NH—, R17 is chosen from lower-alkyl-; cyclohexyl-; phenyl-; and phenyl substituted with halo, lower-alkyl-, loweralkoxy, or lower-alkylsulfanyl-.
  • In another particular embodiment, when R3 is R17NH—, R17 is isopropyl-, butyl-, cyclohexyl-, phenyl-, bromophenyl-, dichlorophenyl-, methoxyphenyl-, ethylphenyl-, tolyl-, trifluoromethylphenyl or methylthiophenyl-.
  • In a particular embodiment, when R3 is R15O—, R15 is chosen from lower-alkyl-; cyclohexyl-; phenyl-; and phenyl substituted with halo, lower-alkyl-, loweralkoxy, or lower-alkylsulfanyl-.
  • In a most particular embodiment, when R3 is R15O—, R15 is isopropyl-, butyl-, cyclohexyl-, phenyl-, bromophenyl-, dichlorophenyl-, methoxyphenyl-, ethylphenyl-, tolyl-, trifluoromethylphenyl or methylthiophenyl-.
  • R3a
  • When R12 is —NR4(SO2R3a), R4 is as described above and R3a is chosen from C1-C13 alkyl-; phenyl-; naphthyl-; phenyl substituted-with cyano, halo, lower-alkyl-, lower-alkoxy, nitro, methylenedioxy, or trifluoromethyl-; biphenylyl and heteroaryl-. More suitably, R3a is chosen from phenyl substituted with halo, lower-alkyl-, lower-alkoxy, cyano, nitro, methlenedioxy, or trifluoromethyl-; and naphthyl-.
  • R3b
  • When R12 is —NR4(CH2R3b), R4 is as described above and R3b is chosen from C1-C13 alkyl-; substituted lower-alkyl-; phenyl-; naphthyl-; phenyl substituted with cyano, halo, lower-alkyl-, lower-alkoxy, nitro, methylenedioxy, or trifluoromethyl-; biphenylyl-, benzyl and heterocyclyl-. Most suitably, R3b is chosen from phenyl substituted with one or more halo, methyl-, cyano, trifluoromethyl-, trifluoromethoxy, carboxy, or methoxycarbonyl groups; piperidinyl-; and naphthyl-. Even more suitably, R3b is halophenyl-, methylhalophenyl-, polyhalophenyl-, tolyl-, dimethylphenyl-, methoxyphenyl-, dimethoxyphenyl-, cyanophenyl-, trifluoromethylphenyl-, trifluorometoxyphenyl-, bis(trifluoromethyl)phenyl-, carboxyphenyl-, t-butylphenyl-, methoxycarbonylphenyl-, piperidinyl-, and naphthyl-.
  • Particular Subgenus
  • In a particular subgenus of compounds of Formula I,
      • R1 is optionally substituted aryl-C1-C4-alkyl-, optionally substituted heteroaryl-C1-C4-alkyl-, or naphthalenylmethyl;
      • R2 is optionally substituted C1-C4-alkyl-;
      • R2 is hydrogen;
      • R2′ is hydrogen, methyl, or cyano;
      • R5, R6, and R8 are hydrogen; and
      • R12 is optionally substituted imidazolyl-, optionally substituted imidazolinyl-, —NHR4; —N(R4)(COR3); —N(R4)(SO2R3a); or —N(R4)(CH2R3b).
  • In a particular subgenus of compounds of Formula I wherein R12 is optionally substituted imidazolyl-,
      • R1, R2, R2′, R5, R6, R7, and R8 are as defined above;
      • R9 is lower-alkyl; phenyl-; or phenyl- substituted with one or more of the following groups: methyl, methoxy, trifluoromethyl, or halo; and
      • R13 is hydrogen and R13′ is substituted C1-C4 alkyl- (especially, aminomethyl-, aminoethyl-, aminopropyl-, acetylamino-methyl-, acetylaminoethyl-, benzyloxycarbonylamino-methyl- or benzyloxycarbonylamino-ethyl-.)
  • In a particular subgenus of compounds of Formula I wherein R12 is optionally substituted imidazolinyl-,
      • R1, R2, R2′, R5, R6, R7, and R8 are as defined above;
      • R14 is lower-alkyl; phenyl-; or phenyl- substituted with one or more of the following groups: methyl, methoxy, trifluoromethyl, or halo; and
      • R10, R10′, R11′, and R11 are independently hydrogen or optionally substituted C1-C4 alkyl-. More particularly, R11′ and R11 are hydrogen.
  • In a particular subgenus of compounds of Formula I wherein R12 is —NHR4. R1, R2, R2′, R5, R6, R7, and R8 are as defined above;
      • R4 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, and optionally substituted heterocyclyl-.
  • In a particular subgenus of compounds of Formula I wherein R12 is —NR4(COR3).
      • R1, R2, R2′, R5, R6, R7, and R8 are as defined above;
      • R4 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, and optionally substituted heterocyclyl- and
      • R3 is selected from hydrogen, optionally substituted alkyl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, optionally substituted heteroaryl-, optionally substituted aryl-, R15O— and R17—NH—, wherein R15 is chosen from optionally substituted alkyl and optionally substituted aryl and R17 is chosen from hydrogen, optionally substituted alkyl and optionally substituted aryl.
  • More particularly, R1, R2, R2′, R5, R6, R7, and R8 are as defined above;
      • R4 is selected from optionally substituted lower-alkyl-, optionally substituted cyclohexyl-; phenyl substituted with hydroxy, lower-alkoxy, or lower-alkyl-; benzyl-; heteroarylmethyl-; heteroarylethyl-; heteroarylpropyl- (especially R4 is R16-alkylene-, and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, carboxy, hydroxyl-, and N-heterocyclyl-); and
      • R3 is selected from hydrogen, optionally substituted alkyl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, optionally substituted heteroaryl-, optionally substituted aryl-, R15O— and R17—NH—, wherein R15 is chosen from optionally substituted alkyl and optionally substituted aryl and R17 is chosen from hydrogen, optionally substituted alkyl and optionally substituted aryl.
  • In a particular subgenus of compounds of Formula I wherein R12 is —NR4(COR3).
      • R1, R2, R2′, R5, R6, R7, and R8 are as defined above;
      • R4 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, and optionally substituted heterocyclyl- and and
      • R3 is selected from optionally substituted alkyl-; aryl-; substituted aryl-; benzyl-; and optionally substituted heteroaryl-.
  • In a particular subgenus of compounds of Formula I wherein R12 is —NR4(COR3),
      • R1, R2, R2′, R5, R6, R7, and R8 are as defined above;
      • R3 is tolyl-, halophenyl-, halomethylphenyl-, hydroxymethylphenyl-, methylenedioxyphenyl-, formylphenyl or cyanophenyl-; and
      • R4 is optionally substituted lower-alkyl-, optionally substituted cyclohexyl-; phenyl substituted with hydroxy, lower-alkoxy or lower-alkyl-; benzyl-; heteroarylmethyl-; heteroarylethyl-; or heteroarylpropyl- (especially R4 is R16-alkylene- and R16 is alkoxy, amino, alkylamino, dialkylamino, carboxy, guanidine, hydroxyl, or N-heterocyclyl-).
  • In a particular subgenus of compounds of Formula I wherein R12 is —N(R4)(CH2R3b),
      • R1, R2, R2′, R5, R6, R7, and R8 are as defined above;
      • R4 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, and optionally substituted heterocyclyl- and
      • R3b is chosen from phenyl substituted with one or more halo, methyl-, cyano, trifluoromethyl-, trifluoromethoxy, carboxy, or methoxycarbonyl groups; piperidinyl-; and naphthyl-.
  • In a particular subgenus of compounds of Formula I wherein R12 is —NR4(SO2R3a),
      • R1, R2, R2′, R5, R6, R7, and R8 are as defined above;
      • R4 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, and optionally substituted heterocyclyl- and
      • R3a is chosen from phenyl substituted with halo, lower-alkyl-, lower-alkoxy, cyano, nitro, methylenedioxy, or trifluoromethyl-; and naphthyl-.
  • Particular compounds include:
    • N-(3-Amino-propyl)-N-[1-(2-benzyl-4-methoxy-1-oxo-1,2-dihydro-isoquinolin-3-yl)-2-methyl-propyl]-4-methyl-benzamide;
    • N-(3-Amino-propyl)-N-[1-(2-benzyl-4-methoxy-1-oxo-1,2-dihydro-isoquinolin-3-yl)-2-methyl-propyl]-2-methoxy-acetamide;
    • 3-(1-Amino-2-methyl-propyl)-2-benzyl-6-chloro-2H-isoquinolin-1-one;
    • N-(3-Amino-propyl)-N-[1-(2-benzyl-6-chloro-1-oxo-1,2-dihydro-isoquinolin-3-yl)-2-methyl-propyl]-4-methyl-benzamide;
    • N-(3-Amino-propyl)-N-[1-(2-benzyl-6-chloro-1-oxo-1,2-dihydro-isoquinolin-3-yl)-2-methyl-propyl]-2-methoxy-acetamide;
    • N-(3-Amino-propyl)-N-[1-(2-benzyl-6-chloro-1-oxo-1,2-dihydro-isoquinolin-3-yl)-2-methyl-propyl]-4-bromo-benzamide;
    • 2-Benzyl-6-chloro-3-[1-(4,4-dimethyl-2-p-tolyl-4,5-dihydro-imidazol-1-yl)-2-methyl-propyl]-2H-isoquinolin-1-one;
    • 2-Benzyl-6-chloro-3-{1-[2-(3,4-dimethoxy-phenyl)-4,4-dimethyl-4,5-dihydro-imidazol-1-yl]-2-methyl-propyl}-2H-isoquinolin-1-one;
    • 2-Benzyl-6-chloro-3-{1-[2-(3,4-dichloro-phenyl)-4,4-dimethyl-4,5-dihydro-imidazol-1-yl]-2-methyl-propyl}-2H-isoquinolin-1-one;
    • 2-Benzyl-6-chloro-3-[1-(4,4-dimethyl-2-m-tolyl-4,5-dihydro-imidazol-1-yl)-2-methyl-propyl]-2H-isoquinolin-l -one;
    • 2-Benzyl-6-chloro-3-{1-[4,4-dimethyl-2-(3-trifluoromethyl-phenyl)-4,5-dihydro-imidazol-1-yl]-2-methyl-propyl}-2H-isoquinolin-1-one;
    • 2-Benzyl-6-chloro-3-{1-[2-(3-fluoro-phenyl)-4,4-dimethyl-4,5-dihydro-imidazol-1-yl]-2-methyl-propyl}-2H-isoquinolin-1-one;
    • 2-Benzyl-6-chloro-3-{1-[2-(3-fluoro-4-methyl-phenyl)-4,4-dimethyl-4,5-dihydro-imidazol-1-yl]-2-methyl-propyl}-2H-isoquinolin-1-one;
    • 2-Benzyl-6-chloro-3-[1-(2-isopropyl-4,4-dimethyl-4,5-dihydro-imidazol-1-yl)-2-methyl-propyl]-2H-isoquinolin-1-one;
    • 2-Benzyl-6-chloro-3-{1-[2-(4-methoxy-phenyl)-4,4-dimethyl-4,5-dihydro-imidazol-1-yl]-2-methyl-propyl}-2H-isoquinolin-1-one; and
    • 2-Benzyl-3-{1-[2-(4-bromo-phenyl)-4,4-dimethyl-4,5-dihydro-imidazol-1-yl]-2-methyl-propyl}-6-chloro-2H-isoquinolin-1-one.
    Utility, Testing and Administration
  • General Utility
  • Once made, the compounds of the invention find use in a variety of applications involving alteration of mitosis. As will be appreciated by those skilled in the art, mitosis may be altered in a variety of ways; that is, one can affect mitosis either by increasing or decreasing the activity of a component in the mitotic pathway. Stated differently, mitosis may be affected (e.g., disrupted) by disturbing equilibrium, either by inhibiting or activating certain components. Similar approaches may be used to alter meiosis.
  • In a particular embodiment, the compounds of the invention are used to inhibit mitotic spindle formation, thus causing prolonged cell cycle arrest in mitosis. By “inhibit” in this context is meant decreasing or interfering with mitotic spindle formation or causing mitotic spindle dysfunction. By “mitotic spindle formation” herein is meant organization of microtubules into bipolar structures by mitotic kinesins. By “mitotic spindle dysfunction” herein is meant mitotic arrest and monopolar spindle formation.
  • The compounds of the invention are useful to bind to, and/or inhibit the activity of, a mitotic kinesin, KSP. In one embodiment, the KSP is human KSP, although the compounds may be used to bind to or inhibit the activity of KSP kinesins from other organisms. In this context, “inhibit” means either increasing or decreasing spindle pole separation, causing malformation, i.e., splaying, of mitotic spindle poles, or otherwise causing morphological perturbation of the mitotic spindle. Also included within the definition of KSP for these purposes are variants and/or fragments of KSP. See U.S. Pat. No. 6,437,115, hereby incorporated by reference in its entirety. The compounds of the invention have been shown to have specificity for KSP. However, the present invention includes the use of the compounds to bind to or modulate other mitotic kinesins.
  • The compounds of the invention are used to treat cellular proliferation diseases. Such disease states which can be treated by the compounds, compositions and methods provided herein include, but are not limited to, cancer (further discussed below), autoimmune disease, fungal disorders, arthritis, graft rejection, inflammatory bowel disease, cellular proliferation induced after medical procedures, including, but not limited to, surgery, angioplasty, and the like. Treatment includes inhibiting cellular proliferation. It is appreciated that in some cases the cells may not be in an abnormal state and still require treatment. Thus, in one embodiment, the invention herein includes application to cells or individuals afflicted or subject to impending affliction with any one of these disorders or states.
  • The compounds, compositions and methods provided herein are particularly deemed useful for the treatment of cancer including solid tumors such as skin, breast, brain, cervical carcinomas, testicular carcinomas, etc. More particularly, cancers that may be treated by the compounds, compositions and methods of the invention include, but are not limited to: Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma; rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meninoiosarcoma, gliomatosis), brain (astrocytonia, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastonma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig, cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarconma), fallopian tubes (carcinoma); Hematologic: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma); Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal glands: neuroblastoma. Thus, the term “cancerous cell” as provided herein, includes a cell afflicted by any one of the above identified conditions.
  • Testing
  • For assay of KSP-modulating activity, generally either KSP or a compound according to the invention is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g., a microtiter plate, an array, etc.). The insoluble support may be made of any material to which the sample can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, Teflon™, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the sample is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the sample and is nondiffusable. Particular methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to “sticky” or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the sample, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.
  • The compounds of the invention may be used on their own to inhibit the activity of a mitotic kinesin, particularly KSP. In one embodiment, a compound of the invention is combined with KSP and the activity of KSP is assayed. Kinesin (including KSP) activity is known in the art and includes one or more kinesin activities. Kinesin activities include the ability to affect ATP hydrolysis; microtubule binding; gliding and polymerization/depolymerization (effects on microtubule dynamics); binding to other proteins of the spindle; binding to proteins involved in cell-cycle control; serving as a substrate to other enzymes, such as kinases or proteases; and specific kinesin cellular activities such as spindle pole separation.
  • Methods of performing motility assays are well known to those of skill in the art. (See e.g., Hall, et al. (1996), Biophys. J., 71: 3467-3476, Turner et al., 1996, AnaL Biochem. 242 (1):20-5; Gittes et al., 1996, Biophys. J. 70(1): 418-29; Shirakawa et al., 1995, J. Exp. BioL 198: 1809-15; Winkelmann et al., 1995, Biophys. J. 68: 2444-53; Winkelmann et al., 1995, Biophys. J. 68: 72S.)
  • Methods known in the art for determining ATPase hydrolysis activity also can be used. Suitably, solution based assays are utilized. U.S. Pat. No. 6,410,254, hereby incorporated by reference in its entirety, describes such assays. Alternatively, conventional methods are used. For example, Pi release from kinesin can be quantified. In one embodiment, the ATPase hydrolysis activity assay utilizes 0.3 M PCA (perchloric acid) and malachite green reagent (8.27 mM sodium molybdate II, 0.33 mM malachite green oxalate, and 0.8 mM Triton X-100). To perform the assay, 10 μL of the reaction mixture is quenched in 90 μL of cold 0.3 M PCA. Phosphate standards are used so data can be converted to mM inorganic phosphate released. When all reactions and standards have been quenched in PCA, 100 μL of malachite green reagent is added to the relevant wells in e.g., a microtiter plate. The mixture is developed for 10-15 minutes and the plate is read at an absorbance of 650 nm. If phosphate standards were used, absorbance readings can be converted to mM Pi and plotted over time. Additionally, ATPase assays known in the art include the luciferase assay.
  • ATPase activity of kinesin motor domains also can be used to monitor the effects of agents and are well known to those skilled in the art. In one embodiment ATPase assays of kinesin are performed in the absence of microtubules. In another embodiment, the ATPase assays are performed in the presence of microtubules. Different types of agents can be detected in the above assays. In a one embodiment, the effect of an agent is independent of the concentration of microtubules and ATP. In another embodiment, the effect of the agents on kinesin ATPase can be decreased by increasing the concentrations of ATP, microtubules or both. In yet another embodiment, the effect of the agent is increased by increasing concentrations of ATP, microtubules or both.
  • Compounds that inhibit the biochemical activity of KSP in vitro may then be screened in vivo. In vivo screening methods include assays of cell cycle distribution, cell viability, or the presence, morphology, activity, distribution, or number of mitotic spindles. Methods for monitoring cell cycle distribution of a cell population, for example, by flow cytometry, are well known to those skilled in the art, as are methods for determining cell viability. See for example, U.S. Pat. No. 6,437,115, hereby incorporated by reference in its entirety. Microscopic methods for monitoring spindle formation and malformation are well known to those of skill in the art (see, e.g., Whitehead and Rattner (1998), J. Cell Sci. 111:2551-61; Galgio et al, (1996) J. Cell Biol., 135:399-414), each incorporated herein by reference in its entirety.
  • The compounds of the invention inhibit the KSP kinesin. One measure of inhibition is IC50, defined as the concentration of the compound at which the activity of KSP is decreased by fifty percent relative to a control. Preferred compounds have IC50's of less than about 1 mM, with preferred embodiments having IC50's of less than about 100 μM, with more preferred embodiments having, IC50's of less than about 10 μM, with particularly preferred embodiments having IC50's of less than about 1 μM, and especially preferred embodiments having IC50's of less than about 100 nM, and with the most preferred embodiments having IC50's of less than about 10 nM. Measurement of IC50 is done using an ATPase assay such as described herein.
  • Another measure of inhibition is Ki. For compounds with IC50's less than 1 μM, the Ki or Kd is defined as the dissociation rate constant for the interaction of the compounds described herein with KSP. Preferred compounds have Ki's of less than about 100 μM, with preferred embodiments having Ki's of less than about 10 μM, and particularly preferred embodiments having Ki's of less than about 1 μM and especially preferred embodiments having Ki's of less than about 100 nM, and with the most preferred embodiments having Ki's of less than about 10 nM.
  • The Ki for a compound is determined from the IC50 based on three assumptions and the Michaelis-Menten equation. First, only one compound molecule binds to the enzyme and there is no cooperativity. Second, the concentrations of active enzyme and the compound tested are known (i.e., there are no significant amounts of impurities or inactive forms in the preparations). Third, the enzymatic rate of the enzyme-inhibitor complex is zero. The rate (i.e., compound concentration) data are fitted to the equation: V = V max ⁢ E 0 [ I - ( E 0 + I 0 + Kd ) - ( E 0 + I 0 + Kd ) 2 - 4 ⁢ E 0 ⁢ I 0 2 ⁢ E 0 ]
    where V is the observed rate, Vmax is the rate of the free enzyme, I0 is the inhibitor concentration, E0 is the enzyme concentration, and Kd is the dissociation constant of the enzyme-inhibitor complex.
  • Another measure of inhibition is GI50, defined as the concentration of the compound that results in a decrease in the rate of cell growth by fifty percent. Preferred compounds have GI50's of less than about 1 mM; those having a GI50 of less than about 20 μM are more preferred; those having a GI50 of less than about 10 μM more so; those having a GI50 of less than about 1 μM more so; those having a GI50 of less than about 100 nM more so; and those having a GI50 of less than about 10 nM even more so. Measurement of GI50 is done using a cell proliferation assay such as described herein. Compounds of this class were found to inhibit cell proliferation.
  • In vitro potency of small molecule inhibitors is determined, for example, by assaying human ovarian cancer cells (SKOV3) for viability following a 72-hour exposure to a 9-point dilution series of compound. Cell viability is determined by measuring the absorbance of formazon, a product formed by the bioreduction of MTS/PMS, a commercially available reagent. Each point on the dose-response curve is calculated as a percent of untreated control cells at 72 hours minus background absorption (complete cell kill).
  • Anti-proliferative compounds that have been successfully applied in the clinic to treatment of cancer (cancer chemotherapeutics) have GI50's that vary greatly. For example, in A549 cells, paclitaxel GI50 is 4 nM, doxorubicin is 63 nM, 5-fluorouracil is 1 μM, and hydroxyurea is 500 μM (data provided by National Cancer Institute, Developmental Therapeutic Program, http://dtp.nci.nih.gov/). Therefore, compounds that inhibit cellular proliferation, irrespective of the concentration demonstrating inhibition, have potential clinical usefulness.
  • To employ the compounds of the invention in a method of screening for compounds that bind to [(SP kinesin, the KSP is bound to a support, and a compound of the invention is added to the assay. Alternatively, the compound of the invention is bound to the support and KSP is added. Classes of compounds among which novel binding agents may be sought include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for candidate agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.
  • The determination of the binding of the compound of the invention to KSP may be done in a number of ways. In one embodiment, tile compound is labeled, for example, with a fluorescent or radioactive moiety, and binding is determined directly. For example, this may be done by attaching all or a portion of KSP to a solid support, adding a labeled test compound (for example a compound of the invention in which at least one atom has been replaced by a detectable isotope), washing off excess reagent, and determining whether the amount of the label is that present on the solid support.
  • By “labeled” herein is meant that the compound is either directly or indirectly labeled with a label which provides a detectable signal, e.g., radioisotope, fluorescent tag, enzyme, antibodies, particles such as magnetic particles, chemiluminescent tag, or specific binding molecules, etc. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc. For the specific binding members, the complementary member would normally be labeled with a molecule which provides for detection, in accordance with known procedures, as outlined above. The label can directly or indirectly provide a detectable signal.
  • In some embodiments, only one of the components is labeled. For example, the kinesin proteins may be labeled at tyrosine positions using 125I, or with fluorophores. Alternatively, more than one component may be labeled with different labels; using 125I for the proteins, for example, and a fluorophor for the antimitotic agents.
  • The compounds of the invention may also be used as competitors to screen for additional drug candidates. “Candidate agent” or “drug candidate” or grammatical equivalents as used herein describe any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for bioactivity. They may be capable of directly or indirectly altering the cellular proliferation phenotype or the expression of a cellular proliferation sequence, including both nucleic acid sequences and protein sequences. In other cases, alteration of cellular proliferation protein binding and/or activity is screened. Screens of this sort may be performed either in the presence or absence of microtubules. In the case where protein binding or activity is screened, particular embodiments exclude molecules already known to bind to that particular protein, for example, polymer structures such as microtubules, and energy sources such as ATP. Particular embodiments of assays herein include candidate agents which do not bind the cellular proliferation protein in its endogenous native state termed herein as “exogenous” agents. In another embodiment, exogenous agents further exclude antibodies to KSP.
  • Candidate agents can encompass numerous chemical classes, though typically they are organic molecules, preferably they are small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding and lipophilic binding, and typically include at least an amine, carbonyl-, hydroxyl-, ether, or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof.
  • Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, and/or amidification to produce structural analogs.
  • Competitive screening assays may be done by combining KSP and a drug candidate in a first sample. A second sample comprises a compound of the present invention, KSP and a drug candidate. This may be performed in either the presence or absence of microtubules. The binding of the drug candidate is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of a drug candidate capable of binding to KSP and potentially inhibiting its activity. That is, if the binding of the drug candidate is different in the second sample relative to the first sample, the drug candidate is capable of binding to KSP.
  • In a particular embodiment, the binding of the candidate agent to KSP is determined through the use of competitive binding assays. In this embodiment, the competitor is a binding moiety known to bind to KSP, such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding as between the candidate agent and the binding moiety, with the binding moiety displacing the candidate agent.
  • In one embodiment, the candidate agent is labeled. Either the candidate agent, or the competitor, or both, is added first to KSP for a time sufficient to allow binding, if present. Incubations may be performed at-any temperature which facilitates optimal activity, typically between 4 and 40° C.
  • Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high throughput screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.
  • In another embodiment, the competitor is added first, followed by the candidate agent. Displacement of the competitor is an indication the candidate agent is binding to KSP and thus is capable of binding to, and potentially inhibiting, the activity of KSP. In this embodiment, either component can be labeled. Thus, for example, if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the candidate agent is labeled, the presence of the label on the support indicates displacement.
  • In an alternative embodiment, the candidate agent is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate the candidate agent is bound to KSP with a higher affinity. Thus, if the candidate agent is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate the candidate agent is capable of binding to KSP.
  • Inhibition is tested by screening for candidate agents capable of inhibiting the activity of KSP comprising the steps of combining a candidate agent with KSP, as above, and determining an alteration in the biological activity of KSP. Thus, in this embodiment, the candidate agent should both bind to KSP (although this may not be necessary), and alter its biological or biochemical activity as defined herein. The methods include both in vitro screening methods and in vivo screening of cells for alterations in cell cycle distribution, cell viability, or for the presence, morpohology, activity, distribution, or amount of mitotic spindles, as are generally outlined above.
  • Alternatively, differential screening may be used to identify drug candidates that bind to the native KSP, but cannot bind to modified KSP.
  • Positive controls and negative controls may be used in the assays. Suitably all control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, all samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.
  • A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g., albumin, detergents, etc which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in any order that provides for the requisite binding.
  • Administration
  • Accordingly, the compounds of the invention are administered to cells. By “administered” herein is meant administration of a therapeutically effective dose of a compound of the invention to a cell either in cell culture or in a patient. By “therapeutically effective dose” herein is meant a dose that produces the effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques. As is known in the art, adjustments for systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art. By “cells” herein is meant any cell in which mitosis or meiosis can be altered.
  • A “patient” for the purposes of the present invention includes both humans and other animals, particularly mammals, and other organisms. Thus the methods are applicable to both human therapy and veterinary applications. In a particular embodiment the patient is a mammal, and more particularly, the patient is human.
  • Compounds of the invention having the desired pharmacological activity may be administered, generally as a pharmaceutically acceptable composition comprising an pharmaceutical excipient, to a patient, as described herein. Depending upon the manner of introduction, the compounds may be formulated in a variety of ways as discussed below. The concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt. %.
  • The agents may be administered alone or in combination with other treatments, i.e., radiation, or other chemotherapeutic agents such as the taxane class of agents that appear to act on microtubule formation or the camptothecin class of topoisomerase I inhibitors. When used, other chemotherapeutic agents may be administered before, concurrently, or after administration of a compound of the present invention. In one aspect of the invention, a compound of the present invention is co-administered with one or more other chemotherapeutic agents. By “co-administer” it is meant that the present compounds are administered to a patient such that the present compounds as well as the co-administered compound may be found in the patient's bloodstream at the same time, regardless when the compounds are actually administered including simultaneously.
  • The administration of the compounds and compositions of the present invention can be done in a variety of ways, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, for example, in the treatment of wounds and inflammation, the compound or composition may be directly applied as a solution or spray.
  • Pharmaceutical dosage forms include a compound of formula I or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof, and one or more pharmaceutical excipients. As is known in the art, pharmaceutical excipients are secondary ingredients which function to enable or enhance the delivery of a drug or medicine in a variety of dosage forms (e.g.: oral forms such as tablets, capsules, and liquids; topical forms such as dermal, opthalmic, and otic forms; suppositories; injectables; respiratory forms and the like). Pharmaceutical excipients include inert or inactive ingredients, synergists or chemicals that substantively contribute to the medicinal effects of the active ingredient. For example, pharmaceutical excipients may function to improve flow characteristics, product uniformity, stability, taste, or appearance, to ease handling and administration of dose, for convenience of use, or to control bioavailability. While pharmaceutical excipients are commonly described as being inert or inactive, it is appreciated in the art that there is a relationship between the properties of the pharmaceutical excipients and the dosage forms containing them.
  • Pharmaceutical excipients suitable for use as carriers or diluents are well known in the art, and may be used in a variety of formulations. See, e.g., Remington's Pharmaceutical Sciences, 18th Edition, A. R. Gennaro, Editor, Mack Publishing Company (1990); Remington: The Science and Practice of Pharmacy, 20th Edition, A. R. Gennaro, Editor, Lippincott Williams & Wilkins (2000); Handbook of Pharmaceutical Excipients, 3rd Edition, A. H. Kibbe, Editor, American Pharmaceutical Association, and Pharmaceutical Press (2000); and Handbook of Pharmaceutical Additives, compiled by Michael and Irene Ash, Gower (1995), each of which is incorporated herein by reference for all purposes.
  • Oral solid dosage forms such as tablets will typically comprise one or more pharmaceutical excipients, which may for example help impart satisfactory processing and compression characteristics, or provide additional desirable physical characteristics to the tablet. Such pharmaceutical excipients may be selected from diluents, binders, glidants lubricants, disintegrants, colors, flavors, sweetening agents, polymers, waxes or other solubility-retarding materials.
  • Compositions for intravenous administration will generally comprise intravenous fluids, i.e., sterile solutions of simple chemicals such as sugars, amino acids or electrolytes, which can be easily carried by the circulatory system and assimilated. Such fluids are prepared with water for injection USP.
  • Fluids used commonly for intravenous (IV) use are disclosed in Remington, the Science and Practice of Pharmacy [full citation previously provided], and include:
  • alcohol (e.g., in dextrose and water (“D/W”) [e.g., 5% dextrose] or dextrose and water [e.g., 5% dextrose] in normal saline solution (“NSS”); e.g. 5% alcohol);
  • synthetic amino acid such as Aminosyn, FreAmine, Travasol, e.g., 3.5 or 7; 8.5; 3.5, 5.5 or 8.5% respectively;
  • ammonium chloride e.g., 2.14%;
  • dextran 40, in NSS e.g., 10% or in D5/W e.g., 10%;
  • dextran 70, in NSS e.g., 6% or in D5/W e.g., 6%;
  • dextrose (glucose, D5/W) e.g., 2.5-50%;
  • dextrose and sodium chloride e.g., 5-20% dextrose and 0.22-0.9% NaCl;
  • lactated Ringer's (Hartmann's) e.g., NaCl 0.6%, KCl 0.03%, CaCl2 0.02%;
  • lactate 0.3%;
  • mannitol e.g., 5%, optionally in combination with dextrose e.g., 10% or NaCl e.g., 15 or 20%;
  • multiple electrolyte solutions with varying combinations of electrolytes, dextrose, fructose, invert sugar Ringer's e.g., NaCl 0.86%, KCl 0.03%, CaCl2 0.033%;
  • sodium bicarbonate e.g., 5%;
  • sodium chloride e.g., 0.45, 0.9, 3, or 5%;
  • sodium lactate e.g., 1/6 M, and
  • sterile water for injection
  • The pH of such fluids may vary, and will typically be from 3.5 to 8 such in the art.
  • The following examples serve to more ftilly describe the manner of using the above-described invention, as well as to set forth the best modes contemplated for carrying out various aspects of the invention. It is understood that these examples in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.
    • EXAMPLES Example 1
  • Synthesis of Compounds
    Figure US20060019988A1-20060126-C00020
    Figure US20060019988A1-20060126-C00021
  • A solution of 4-chloro-2-iodobenzoic acid 1 (25 g, 88.7 mmol), SOCl2 (100 mL), and DMF (few drops) was warmed gently with a heat gun until the mixture became homogeneous (15 mins). The solution was maintained at 23° C. for an additional 30 mins, then the solution was concentrated. MeOH (200 mL) was added to the crude residue and the solution was maintained at 23° C. for 30 mins. The solution was concentrated and the crude residue was then dissolved in 10:1 hexanes:EtOAc and passed through a plug of silica gel. The eluent was concentrated to provide 26.2 g (100%) of ester 2 as a colorless oil, which solidified upon standing under high vacuum (0.1 Torr).
  • A mixture of ester 2 (2.35 g, 7.94 mmol), acetylene 31 (1.72 g, 8.7 mml), Pd(PPh3)Cl2 (140 mg, 0.20 mmol), Cul (19 mg, 0.1 mmol), and TEA (35 mL) was maintained at 50° C. for 1 h. The reaction mixture was diluted with EtOAc (200 mL), washed with water (100 mL), then brine (100 mL). The organic layer was dried (MgSO4) and concentrated. The crude residue was purified by flash column chromatography (10:1 hexanes:EtOAc) to provide 2.88 g (100%) of 4.
    1 Fehrentz, J.-A.; Castro, B. Synthesis 1983, 676. Goel. O.; Krolls, U.; Steir, M.; Kesten, S. Org. Syn. 1988, 67, 69.
  • Ester 4 (2.88 g, 7.94.mmol), KOH (930 mg, 16.5 mmol), MeOH (15 mL), THF (15 mL), and H2O (15 mL) was maintained at 50° C. for exactly 30 mins. The reaction was diluted with EtOAc (100 mL) and washed with 1N HCl (20 mL) and brine (20 mL). The organic layer was dried (MgSO4) and concentrated to provide 2.76 g of acid 5 (99%), which was used without further purification.
  • Pd(MeCN)2Cl2 (98mg, 0.39 mmol) was added to a solution of the crude acid 5 (2.76 g, 7.87 mmol), TEA (3.3 mL) and THF (54 mL). The solution was maintained at 50° C. for 30 mins. The reaction solution was diluted with hexanes (150 mL) and passed through a plug of silica gel. The plus was rinsed with (5:1 hexanes:EtOAc). The filtrate was concentrated. Hexanes (50 mL) was added to this crude residue and pure 6 precipitated out of solution. This precipitated material was filtered and used without further purification. The filtrate was then concentrated and the remaining residue dried onto silica gel (CH2Cl2) and purified by flash column chromatography (10:1 hexanes:EtOAc; 5:1 hexanes:EtOAc; 3:1 hexanes:EtOAc) to provide a combined 2.22 g of 6 (77%, two steps).
  • A solution of isochromenone 6 (2.1 g, 6.0 mmol), BnNH2 (1.96 mL, 17.9 mmol), and PhMe (3.0 mL) was maintained at 140° C. for 1.5 h. The reaction mixture was cooled to 23° C., diluted with EtOAc (50 mL), washed with 1 N HCl (20 mL) and brine (20 mL). The organic layer was dried (MgSO4) and concentrated. The resulting crude residue was used without further purification. A solution of the crude residue, 5% HCl (3.4 mL) and MeOH (17 ml) was maintained at 50° C. for 1.5 h. The product 7 begins to precipitate from the reaction solution after 5 mins as a white solid. After 30 mins, an additional amount of MeOH (5 mL) and 5% HCl (1 mL) was added and the reaction mixture was maintained for an additional 1 h. The reaction mixture was diluted with EtOAc (100 mL), washed with 1 N NaOH (50 mL) and then brine (20 mL). The organic layer was dried (MgSO4) and concentrated. The residue was purified by flash column chromatography (5:1 hexanes:EtOAc) to provide 1.8 g of racemic 7 (68%, two steps).
  • A solution of isoquinolone 7 (2.50 g, 5.68 mmol) and TFA:H2O (97.5:2.5; 25 mL) was maintained at 23° C. for 1 h. The solution was concentrated. The crude residue was diluted with EtOAc (75 mL), washed with 1 N NaOH (20 mL), and brine (20 mL). The organic layer was dried (MgSO4) and concentrated to give 1.83 g of amine 9 (95%) as a white solid.
  • Isoquinolone 8 (131 mg, 0.34 mmol), aldehyde 9 (115 mg, 0.56 mmol), Na(OAc)3BH (291 mg, 1.38 mmol), and CH2Cl2 (1.1 mL) was maintained at 23° C. for 3 h. The reaction mixture was diluted with EtOAc (20 mL) and washed with 1 N NaOH (5 mL) and brine (5 mL). The organic layer was dried (MgSO4), filtered, and concentrated. The resulting residue was purified by flash column chromatography (3:1 hexanes:EtOAc) to yield 150 mg (85%) of 10.
  • A solution of isoquinolone 10 (143 mg, 0.28 mmol), POCl3 (0.45 mL, 4.8 mmol), and PhMe (14 mL) was heated to 110° C. After 6 h, the reaction mixture was diluted with EtOAc (40 mL) and washed with 1 N NaOH (20 mL) and brine (10 mL). The organic layer was dried (MgSO4), filtered, and concentrated. The resulting residue was purified by flash column chromatography (20:1 CHCl3:MeOH) to yield 99 mg (70%) of 11 as a white solid.
    • Example 2
  • Synthesis of Compounds
    Figure US20060019988A1-20060126-C00022
  • Isoquinolone 8 (515 mg, 1.47 mmol), aldehyde 12 (255 mg, 1.47 mmol), NaCN(OAc)3BH (420 mg, 1.98 mmol), and CH2Cl2 (4.1 mL) was maintained at 23° C. for 2 h. An additional portion of 12 (225 mg, 1.30 mmol) in CH2Cl2 (0.6 mL) was then added. After an additional 3 h, the reaction mixture was diluted with EtOAc (20 mL) and washed with 1 N NaOH (5 mL) and brine (5 mL). The organic layer was dried (MgSO4), filtered, and concentrated. The resulting residue was purified by flash column chromatography (3:1 hexanes:EtOAc; 1:1 hexanes:EtOAc) to yield 630 mg (86%) of 13.
  • To a solution of isoquinolone 13 (85 mg, 0.17 mmol), diisoproylethylamine (DIEA, 0.12 mL, 0.68 mmol), and CH2Cl2 (0.6 mL) at 23° C. was added p-toluoyl chloride (45 μL, 34 mmol). After 4 h, the reaction mixture was diluted with EtOAc (20 mL) and washed with saturated aqueous NaHCO3 (5 mL) and brine (5 mL). The organic layer was dried (MgSO4), filtered, and concentrated. The resulting residue was purified by flash column chromatography (3:1 hexanes:EtOAc) to yield 83 mg (80%) of 14.
  • Isoquinolone 14 (80 mg, 0.13 mmol) and TFA:H2O (97.5:2.5, 2 mL) was maintained at 23° C. for 1 h. The reaction mixture was concentrated. The residue was dissolved in EtOAc (20 mL) and washed with 1 N NaOH (5 mL) and brine (5 mL). The organic layer was dried (MgSO4), filtered, and concentrated to provide 65 mg (98%) of 15 as a white solid which was deemed >95% pure by 1H NMR and LCMS analysis.
    • Example 3
  • Using the methods of the invention as exemplified in Examples 1 and 2 above, the following compounds were prepared:
    LRMS
    Structure (MH) m/z
    Figure US20060019988A1-20060126-C00023
         		516.2
    Figure US20060019988A1-20060126-C00024
         		470.2
    Figure US20060019988A1-20060126-C00025
         		512.2
    Figure US20060019988A1-20060126-C00026
         		575.8
    Figure US20060019988A1-20060126-C00027
         		528.0
    Figure US20060019988A1-20060126-C00028
         		464.0
    Figure US20060019988A1-20060126-C00029
         		530.0
    Figure US20060019988A1-20060126-C00030
         		516.2
    Figure US20060019988A1-20060126-C00031
         		566.2
    Figure US20060019988A1-20060126-C00032
         		512.2
    Figure US20060019988A1-20060126-C00033
         		565.8
    Figure US20060019988A1-20060126-C00034
         		558.2
    • Example 4
  • Monopolar Spindle Formation Following Application of an Isoquinolone KSP Inhibitor
  • Human tumor cell lines Skov-3 (ovarian) are plated in 96-well plates at densities of 4,000 cells per well, allowed to adhere for 24 hours, and treated with various concentrations of the isoquinolone compounds for 24 hours. Cells are fixed in 4% formaldehyde and stained with antitubulin antibodies (subsequently recognized using fluorescently-labeled secondary antibody) and Hoechst dye (which stains DNA).
  • Visual inspection reveals that the compounds cause cell cycle arrest in the prometaphase stage of mitosis. DNA is condensed and spindle formation is initiated, but arrested cells uniformly display monopolar spindles, indicating that there is an inhibition of spindle pole body separation. Microinjection of anti-KSP antibodies also causes mitotic arrest with arrested cells displaying monopolar spindles.
    • Example 5
  • Inhibition of Cellular Proliferation in Tumor Cell Lines Treated with KSP Inhibitors.
  • Cells are plated in 96-well plates at densities from 1000-2500 cells/well of a 96-well plate and allowed to adhere/grow for 24 hours. They are then treated with various concentrations of drug for 48 hours. The time at which compounds are added is considered T0. A tetrazolium-based assay using the reagent 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (1.S>U.S. Pat. No. 5,185,450) (see Promega product catalog #G3580, CellTiter 96® AQueous One Solution Cell Proliferation Assay) is used to determine the number of viable cells at T0 and the number of cells remaining after 48 hours compound exposure. The number of cells remaining after 48 hours is compared to the number of viable cells at the time of drug addition, allowing for calculation of growth inhibition.
  • The growth over 48 hours of cells in control wells that have been treated with vehicle only (0.25% DMSO) is considered 100% growth and the growth of cells in wells with compounds is compared to this. KSP inhibitors inhibit cell proliferation in human ovarian tumor cell lines (SKOV-3).
  • A Gi50 is calculated by plotting the concentration of compound in μM vs the percentage of cell growth of cell growth in treated wells. The Gi50 calculated for the compounds is the estimated concentration at which growth is inhibited by 50% compared to control, i.e., the concentration at which:
    100×[(Treated48 −T 0)/(Control48 −T 0)]=50.
  • All concentrations of compounds are tested in duplicate and controls are averaged over 12 wells. A very similar 96-well plate layout and GI50 calculation scheme is used by the National Cancer Institute (see Monks, et al., J. Natl. Cancer Inst. 83 :757-766 (1991)). However, the method by which the National Cancer Institute quantitates cell number does not use MTS, but instead employs alternative methods.
    • Example 6
  • Calculation of IC50:
  • Measurement of a compound's IC50 for KSP activity uses an ATPase assay. The following solutions are used: Solution 1 consists of 3 mM phosphoenolpyruvate potassium salt (Sigma P-7127), 2 mM ATP (Sigma A-3377), 1 mM IDTT (Sigma D-9779), 5 μM paclitaxel (Sigma T-7402), 10 ppm antifoam 289 (Sigma A-8436), 25 mM Pipes/KOH pH 6.8 (Sigma P6757), 2 mM MgCl2 (VWR JT400301), and 1 mM EGTA (Sigma E3889). Solution 2 consists of 1 mM NADH (Sigma N8129), 0.2 mg/ml BSA (Sigma A7906), pyruvate kinase 7U/ml, L-lactate dehydrogenase 10 U/ml (Sigma P0294), 100 nM KSP motor domain, 50 μg/ml microtubules, 1 mM DTT (Sigma D9779), 5 μM paclitaxel (Sigma T-7402), 10 ppm antifoam 289 (Sigma A-8436), 25 mM Pipes/KOH pH 6.8 (Sigma P6757), 2 mM MgCl2 (VWR JT4003-01), and 1 mM EGTA (Sigma E3889). Serial dilutions (8-12 two-fold dilutions) of the compounds are made in a 96-well microtiter plate (Corning Costar 3695) using Solution 1. Following serial dilution each well has 50 μl of Solution 1. The reaction is started by adding 50 μl of Solution 2 to each well. This may be done with a multichannel pipettor either manually or with automated liquid handling devices. The microtiter plate is then transferred to a microplate absorbance reader and multiple absorbance readings at 340 nm are taken for each well in a kinetic mode. The observed rate of change, which is proportional to the ATPase rate, is then plotted as a function of the compound concentration. For a standard IC50 determination the data acquired is fit by the following four parameter equation using a nonlinear fitting program (e.g., Grafit 4): y = Range 1 + ( x IC 50 ) s + Background
    where y is the observed rate and x the compound concentration.

Claims (34)

1. A method of inhibiting KSP kinesin activity which comprises contacting said kinesin with an effective amount of a compound having the structure represented by Formula I:
Figure US20060019988A1-20060126-C00035
wherein:
R1 is chosen from optionally substituted phenyl-C1-C4-alkyl-, optionally substituted heteroaryl-C1-C4-alkyl-, and naphthalenylmethyl-;
R2 and R2′ are independently chosen from hydrogen, optionally substituted alkyl-, optionally substituted alkoxy, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, and optionally substituted heteroaralkyl-; or R2 and R2′ taken together form an optionally substituted 3- to 7-membered ring;
R12 is selected from the group consisting of optionally substituted imidazolyl-, optionally substituted imidazolinyl-, —NHR4; —N(R4)(COR3); —N(R4)(SO2R3a); and —N(R4)(CH2R3b);
R3 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, optionally substituted heteroaralkyl-, R15O— and R17—NH—;
R3a is chosen from optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, optionally substituted heteroaralkyl-, and R17—NH—;
R3b is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, and optionally substituted heteroaralkyl-;
R4 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heterocyclyl-, and optionally substituted heteroaralkyl-;
R5, R6, R7 and R8 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted alkoxy, halogen, hydroxyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, optionally substituted aryl and optionally substituted heteroaryl;
R15 is optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, or optionally substituted heteroaralkyl-; and
R17 is chosen from hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, and optionally substituted heteroaralkyl;
a pharmaceutically acceptable salt of a compound of Formula I;
a pharmaceutically acceptable solvate of a compound of Formula I;
or a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt of a compound of Formula I.
2-5. (canceled)
6. A method according to claim 1, wherein R1 is benzyl.
7. A method according to claim 1, wherein R2 and R2′ are independently chosen from hydrogen, optionally substituted alkyl-, optionally substituted alkoxy, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaryl-, and optionally substituted heteroaralkyl-; or R2 and R2′ taken together form an optionally substituted 3- to 7-membered ring.
8. A method according to claim 7, wherein R2 is optionally substituted C1-C4 alkyl-, and R2′ is hydrogen or optionally substituted C1-C4 alkyl-.
9. A method according to claim 8, wherein R2′ is hydrogen and R2 is optionally substituted C1-C4 alkyl-.
10. A method according to claim 9, wherein R2′ is hydrogen and R2 is ethyl or propyl.
11. A method according to claim 10, wherein R2 is i-propyl.
12. A method according to claim 1, wherein if either R2 or R2′ is hydrogen, then the other is not hydrogen.
13. A method according to claim 1, wherein R5, R6, R7, and R8 are independently chosen from hydrogen, hydroxyl, halogen, optionally substituted C1-C4 alkyl-, C1-C4 alkoxy, cyano, amino, substituted amino, or carbamyl-.
14. A method according to claim 13, wherein R5, R6, R7, and R8 are independently methoxy, methyl, trifluoromethyl, cyano, hydrogen or halo.
15. A method according to claim 14, wherein only one of R5, R6, R7, and R8 is not hydrogen.
16. A method according to claim 1, wherein R12 is an optionally substituted imidazolyl- having the formula:
Figure US20060019988A1-20060126-C00036
wherein
R9 is chosen from hydrogen, optionally substituted C1-C8 alkyl-, optionally substituted aryl-, optionally substituted aryl-C1-C4-alkyl-, optionally substituted heteroaryl-C1-C4-alkyl-, optionally substituted aryl-C1-C4-alkoxy, optionally substituted heteroaryl-C1-C4-alkoxy, and optionally substituted heteroaryl-; and
R13 and R13′ are independently hydrogen, optionally substituted C1-C8 alkyl-, optionally substituted aryl-, or optionally substituted aryl-C1-C4-alkyl-.
17. A method according to claim 16, wherein R9 is lower-alkyl; phenyl-; or phenyl- substituted with one or more of the following groups: methyl, methoxy, trifluoromethyl, or halo.
18. A method according to claim 16, wherein R13 is hydrogen and R13′ is optionally substituted substituted C1-C4 alkyl-.
19. A method according to claim 1, wherein R12 is an optionally substituted imidazoline having the formula
Figure US20060019988A1-20060126-C00037
wherein,
R14 is chosen from hydrogen, optionally substituted C1-C8 alkyl-, optionally substituted aryl-, optionally substituted aryl-C1-C4-alkyl-, optionally substituted heteroaryl-, optionally substituted heteroaryl-C1-C4-alkyl-; and
R10, R10′, R11 and R11′ are independently chosen from hydrogen, optionally substituted C1-C8 alkyl-, optionally substituted aryl-, and optionally substituted aryl-C1-C4-alkyl-.
20. A method according to claim 19, wherein R10, R10′, R11′, and R11 are independently hydrogen or optionally substituted C1-C4 alkyl-.
21. A method according to claim 1 wherein R12 is —NHR4, —NR4(COR3), NR4(SO2R3a), or —NR4(CH2R3b) and R4 is R16-alkylene-, and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, carboxy, guanidine, hydroxyl-, and N-heterocyclyl-.
22. A method according to claim 1 wherein R12 is —NR4(COR3) and R3 is selected from hydrogen, optionally substituted alkyl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, optionally substituted heteroaryl-, optionally substituted aryl-, R15O— and R17—NH—, wherein R15 is chosen from optionally substituted alkyl and optionally substituted aryl and R17 is chosen from hydrogen, optionally substituted alkyl and optionally substituted aryl-.
23. A method according to claim 22 wherein R12 is —NR4(COR3) and R3 is tolyl-, halophenyl-, halomethylphenyl-, hydroxymethylphenyl-, methylenedioxyphenyl-, formylphenyl or cyanophenyl-.
24. A method according to claim 21 wherein R3a is chosen from C1-C13 alkyl-; phenyl-; naphthyl-; phenyl substituted with cyano, halo, lower-alkyl-, lower-alkoxy, nitro, methylenedioxy, or trifluoromethyl-; biphenylyl and heteroaryl-.
25. A method according to claim 21 wherein R3b is chosen from C1-C13 alkyl-; substituted lower-alkyl-; phenyl-; naphthyl-; phenyl substituted with cyano, halo, lower-alkyl-, lower-alkoxy, nitro, methylenedioxy, or trifluoromethyl-; biphenylyl-, benzyl and heterocyclyl-.
26. A method according to claim 1 wherein,
R1 is optionally substituted aryl-C1-C4-alkyl-, optionally substituted heteroaryl-C1-C4-alkyl-, or naphthalenylmethyl
R2 is optionally substituted C1-C4-alkyl-;
R2′ is hydrogen;
R7 is hydrogen, methyl, or cyano;
R5, R6, and R8 are hydrogen; and
R12 is optionally substituted imidazolyl-, optionally substituted imidazolinyl-, —NHR4; —N(R4)(COR3); —N(R4)(SO2 R3a); and —N(R4)(CH2R3b).
27. A method according to claim 26 wherein R12 is optionally substituted imidazolyl- having the formula:
Figure US20060019988A1-20060126-C00038
wherein
R9 is lower-alkyl; phenyl-; or phenyl- substituted with one or more of the following groups: methyl, methoxy, trifluoromethyl, or halo;
R13 is hydrogen; and
R13′ is substituted C1-C4 alkyl-.
28. A method according to claim 26 wherein R12 is optionally substituted imidazolinyl- having the formula:
Figure US20060019988A1-20060126-C00039
wherein
R14 is lower-alkyl; phenyl-; or phenyl- substituted with one or more of the following groups: methyl, methoxy, trifluoromethyl, or halo; and
R10, R10′, R11′, and R11 are independently hydrogen or optionally substituted C1-C4 alkyl-.
29. A method according to claim 26 wherein R12 is —NHR4; and
R4 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, and optionally substituted heterocyclyl-.
30. A method according to claim 26 wherein R3 is selected from hydrogen, optionally substituted alkyl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, optionally substituted heteroaryl-, optionally substituted aryl-, R15O— and R17—NH—, wherein R15 is chosen from optionally substituted alkyl and optionally substituted aryl and R17 is chosen from hydrogen, optionally substituted alkyl and optionally substituted aryl.
31. A method according to claim 30 wherein R4 is is R16-alkylene-, and R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, carboxy, hydroxyl-, and N-heterocyclyl-.
32. A method according to claim 31, wherein
R4 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, and optionally substituted heterocyclyl- and
R3 is selected from optionally substituted alkyl-; aryl-; substituted aryl-; benzyl-; and optionally substituted heteroaryl-.
33. A method according to claim 32, wherein R3 is tolyl-, halophenyl-, halomethylphenyl-, hydroxymethylphenyl-, methylenedioxyphenyl-, formylphenyl or cyanophenyl-.
34. A method according to claim 26, wherein R12 is —N(R4)(CH2R3b);
R4 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, and optionally substituted heterocyclyl- and
R3b is chosen from phenyl substituted with one or more halo, methyl-, cyano, trifluoromethyl-, trifluoromethoxy, carboxy, or methoxycarbonyl groups; piperidinyl-; and naphthyl-.
35. A method according to claim 1, wherein R12 is —NR4(SO2R3a);
R4 is chosen from hydrogen, optionally substituted alkyl-, optionally substituted aryl-, optionally substituted aralkyl-, optionally substituted heteroaralkyl-, and optionally substituted heterocyclyl- and
R3a is chosen from phenyl substituted with halo, lower-alkyl-, lower-alkoxy, cyano, nitro, methlenedixoy, or trifluoromethyl-; and naphthyl-.
36. A method according to claim 1, wherein R2 and R2′ are each attached to a stereogenic center having an R-configuration.
37-48. (canceled)
US11/188,287 2002-06-14 2005-07-21 Compounds, compositions, and methods Abandoned US20060019988A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/188,287 US20060019988A1 (en) 2002-06-14 2005-07-21 Compounds, compositions, and methods

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38926502P 2002-06-14 2002-06-14
US38977902P 2002-06-18 2002-06-18
US10/462,002 US7041676B2 (en) 2002-06-14 2003-06-12 Compounds, compositions, and methods
US11/188,287 US20060019988A1 (en) 2002-06-14 2005-07-21 Compounds, compositions, and methods

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/462,002 Continuation US7041676B2 (en) 2002-06-14 2003-06-12 Compounds, compositions, and methods

Publications (1)

Publication Number Publication Date
US20060019988A1 true US20060019988A1 (en) 2006-01-26

Family

ID=29740126

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/462,002 Expired - Fee Related US7041676B2 (en) 2002-06-14 2003-06-12 Compounds, compositions, and methods
US11/188,287 Abandoned US20060019988A1 (en) 2002-06-14 2005-07-21 Compounds, compositions, and methods

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/462,002 Expired - Fee Related US7041676B2 (en) 2002-06-14 2003-06-12 Compounds, compositions, and methods

Country Status (6)

Country Link
US (2) US7041676B2 (en)
EP (1) EP1556357A4 (en)
JP (1) JP2005538062A (en)
AU (1) AU2003236527A1 (en)
CA (1) CA2489367A1 (en)
WO (1) WO2003106426A1 (en)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050234037A1 (en) * 2003-12-08 2005-10-20 Gustave Bergnes Compounds, compositions, and methods
US20090124638A1 (en) * 2004-11-19 2009-05-14 Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
WO2009088990A1 (en) * 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
US20090312319A1 (en) * 2008-01-04 2009-12-17 Intellikine Certain chemical entities, compositions and methods
US20100009963A1 (en) * 2006-04-04 2010-01-14 The Regents Of The University Of California Kinase antagonists
US20100184760A1 (en) * 2008-11-03 2010-07-22 Pingda Ren Benzoxazole kinase inhibitors and methods of use
US20110077268A1 (en) * 2008-03-14 2011-03-31 Yi Liu Kinase inhibitors and methods of use
US20110160232A1 (en) * 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US20110172228A1 (en) * 2008-07-08 2011-07-14 Pingda Ren Kinase inhibitors and methods of use
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8785454B2 (en) 2009-05-07 2014-07-22 Intellikine Llc Heterocyclic compounds and uses thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
AU2014203687B2 (en) * 2008-01-04 2016-04-14 Intellikine Llc Certain chemical entities, compositions and methods
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10131668B2 (en) 2012-09-26 2018-11-20 The Regents Of The University Of California Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies
US12213983B2 (en) 2012-11-01 2025-02-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US7009049B2 (en) * 2002-02-15 2006-03-07 Cytokinetics, Inc. Syntheses of quinazolinones
CN100491358C (en) 2002-05-09 2009-05-27 赛特凯恩蒂克公司 Pyrimidinone compounds, compositions and methods
EP1553931A4 (en) 2002-05-09 2006-08-30 Cytokinetics Inc Compounds, compositions, and methods
AU2003265242A1 (en) 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
CA2489367A1 (en) 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
EP1537089A4 (en) 2002-07-23 2008-04-16 Cytokinetics Inc Compounds compositions and methods
AU2003262747A1 (en) * 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
EP1558083A4 (en) 2002-09-30 2008-04-16 Cytokinetics Inc Compounds, compositions, and methods
EP1680420A4 (en) * 2003-11-07 2008-09-24 Cytokinetics Inc Compounds, compositions, and methods
WO2005113507A1 (en) * 2004-05-21 2005-12-01 Novartis Vaccines And Diagnostics Inc. Substituted quinoline derivatives as mitotic kinesin inhibitors
CA2575188A1 (en) 2004-08-18 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
US20100093767A1 (en) * 2004-12-03 2010-04-15 Takeda San Diego, Inc. Mitotic Kinase Inhibitors
MX2009007260A (en) 2007-01-05 2009-07-10 Novartis Ag Cyclized derivatives as eg-5 inhibitors.
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound

Citations (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962244A (en) * 1971-01-23 1976-06-08 Hoechst Aktiengesellschaft Benzene sulfonyl ureas
US4011324A (en) * 1976-01-20 1977-03-08 Pfizer Inc. Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents
US4734419A (en) * 1985-10-07 1988-03-29 Fujisawa Pharmaceutical Co., Ltd. Quinazoline derivatives, compositions thereof and their use in treating diabetic complications
US4859670A (en) * 1986-03-21 1989-08-22 Hoechst Aktiengesellschaft 2-Azolylmethyl-2-aryl-1,3-dioxolanes and the salts thereof, agents containing same, and the use thereof
US5158959A (en) * 1980-08-30 1992-10-27 Hoechst Aktiengesellschaft Decahydroisoquinoline carboxylic acids
US5342944A (en) * 1993-07-19 1994-08-30 American Cyanamid Company Process for the preparation of 2-alkyl-3,5,6,7- or 8-substituted-4(3H)-quinazolinones
US5444061A (en) * 1991-03-19 1995-08-22 British Technology Group Limited Anti-cancer compounds
US5492915A (en) * 1990-07-24 1996-02-20 Rhone-Poulenc Rorer S.A. Substituted quinolyl compounds exhibiting selective leukotriene B4 antagonist activity
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
US5892114A (en) * 1996-04-18 1999-04-06 Bayer Aktiengesellschaft Hetero-linked phenylglycinolamides
US5939421A (en) * 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
US5948784A (en) * 1994-08-26 1999-09-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
US5948775A (en) * 1997-03-19 1999-09-07 American Home Products Corporation 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
US6245768B1 (en) * 1995-06-05 2001-06-12 Neurogen Corporation 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands
US20010046997A1 (en) * 1998-03-24 2001-11-29 Abraham Donald J. Allosteric inhibitors of pyruvate kinase
US20020032207A1 (en) * 1999-10-29 2002-03-14 Wayne Thompson 2-Cyclohexyl quinazoline NMDA/NR2B antagonists
US20020055519A1 (en) * 1999-10-29 2002-05-09 Thompson Wayne I. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US20020165221A1 (en) * 2000-10-13 2002-11-07 Baxter Anthony David Mediators of hedgehog signaling pathways, compositions and uses related thereto
US20020198326A1 (en) * 1993-11-12 2002-12-26 Taizo Aoyama Polyolefin resin composition
US20030018038A1 (en) * 1999-10-29 2003-01-23 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US20030091946A1 (en) * 2001-04-20 2003-05-15 Shigeki Uehira Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound
US20030119834A1 (en) * 2001-09-05 2003-06-26 Bamdad Cynthia C. Compositions and methods of treatment of cancer
US20030130293A1 (en) * 2001-09-05 2003-07-10 Bamdad Cynthia C. Compositions and methods of treatment of cancer
US20030139457A1 (en) * 2000-03-30 2003-07-24 Curis, Inc. Small organic molecule regulators of cell proliferation
US20030139398A1 (en) * 2001-04-09 2003-07-24 Hoekstra William J. Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
US20030144350A1 (en) * 2001-07-20 2003-07-31 Adipogenix, Inc. Fat accumulation-modulation compounds
US20030158188A1 (en) * 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20030158198A1 (en) * 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20030166933A1 (en) * 2001-11-20 2003-09-04 Gustave Bergnes Process for the racemization of chiral quinazolinones
US20030171387A1 (en) * 2001-11-19 2003-09-11 Dongxu Sun Modulators of Rho C activity
US6627755B1 (en) * 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
US20030195211A1 (en) * 2000-04-25 2003-10-16 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US20030220356A1 (en) * 2002-04-04 2003-11-27 Prabha Ibrahim ABCA-1 elevating compounds
US20030220338A1 (en) * 2001-07-16 2003-11-27 Watkins Will J. Fungal efflux pump inhibitors
US20040048853A1 (en) * 2002-08-21 2004-03-11 Gustave Bergnes Compounds, compositions, and methods
US20040067969A1 (en) * 2002-02-15 2004-04-08 Gustave Bergnes Syntheses of quinazolinones
US20040077668A1 (en) * 2002-05-09 2004-04-22 Cytokinetics, Inc. Compounds, compositins, and methods
US20040077662A1 (en) * 2002-05-09 2004-04-22 Cytokinetics, Inc. Compounds, methods and compositions
US20040077667A1 (en) * 2000-12-11 2004-04-22 Nobuya Matsuoka Quinazolinone derivatives
US20040082567A1 (en) * 2002-06-14 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
US20040092561A1 (en) * 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
US20040116438A1 (en) * 2002-05-23 2004-06-17 Pu-Ping Lu Compounds, compositions, and methods
US20040142949A1 (en) * 2002-07-23 2004-07-22 Gustave Bergnes Compounds, compositions, and methods
US6794379B2 (en) * 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
US20040242596A1 (en) * 2003-05-22 2004-12-02 Kim Kyoung S. Bicyclicpyrimidones and their use to treat diseases
US20040259826A1 (en) * 2001-11-07 2004-12-23 Fraley Mark E. Mitotic kinesin inhibitors
US20050152940A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1249281B (en) 1963-05-18
US3320124A (en) 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
BG16042A3 (en) 1968-11-12 1972-05-20 Nans Ott METHOD FOR OBTAINING NEW 2(1H)-QUINAZOLINONES
US3740442A (en) 1972-01-14 1973-06-19 Sandoz Ag 2-isopropylaminobenzophenones in treating inflammation
US4281127A (en) 1979-07-09 1981-07-28 Hoffmann-La Roche Inc. Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives
AU543928B2 (en) 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
JPH0333118Y2 (en) 1986-02-20 1991-07-12
US5187167A (en) 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US4729996A (en) 1986-05-29 1988-03-08 Harbor Branch Oceanographic Institution, Inc. Antitumor compositions and their methods of use
DE3721855A1 (en) 1987-03-12 1988-09-22 Merck Patent Gmbh AMINO ACID DERIVATIVES
GB8707053D0 (en) 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
US4808590A (en) 1987-07-17 1989-02-28 Harbor Branch Oceanographic Institution, Inc. Antiviral, antitumor and antifungal compositions and their methods of use
US4866084A (en) 1987-07-17 1989-09-12 Harbor Branch Oceanographic Institution, Inc. Topsentin compounds effective against viruses and certain tumors
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US4857530A (en) 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
ATE113953T1 (en) 1988-05-10 1994-11-15 Ici Plc CEPHALOSPORINS, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS.
GB8820129D0 (en) 1988-08-24 1988-09-28 Schering Agrochemicals Ltd Fungicides
GB8827820D0 (en) 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
GB8829296D0 (en) 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
US4970226A (en) 1989-10-03 1990-11-13 Harbor Branch Oceanographic Institution, Inc. Bis-indole imidazole compounds which are useful antitumor and antimicrobial agents
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
US5264439A (en) 1990-02-13 1993-11-23 Merck & Co., Inc. Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element
CA2075627A1 (en) 1990-02-13 1991-08-14 William J. Greenlee Angiotensin ii antagonists incorporating a substituted benzyl element
IL98167A0 (en) 1990-05-30 1992-06-21 Ici Plc Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them
EP0481614A1 (en) 1990-10-01 1992-04-22 Merck & Co. Inc. Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists
US5162325A (en) 1991-05-07 1992-11-10 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element
US5714493A (en) 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
CA2079982A1 (en) 1991-10-07 1993-04-08 Stephen E. De Laszlo Substituted pyrazino (2,3-d)-pyrimidinones as angiotensin ii antagonists
GB9125515D0 (en) 1991-11-29 1992-01-29 Merck Sharp & Dohme Therapeutic agents
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
DK0630376T3 (en) 1992-03-12 1999-06-23 Smithkline Beecham Plc Condensed indole derivatives as 5-HT4 receptor antagonists
GB9205907D0 (en) 1992-03-18 1992-04-29 Cancer Res Inst Royal Anti-cancer compounds
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
WO1993023404A1 (en) 1992-05-19 1993-11-25 Immunopharmaceutics, Inc. Compounds that modulate endothelin activity
GB9220571D0 (en) 1992-09-30 1992-11-11 Ici Plc Quinazoline derivatives
JPH06148835A (en) 1992-11-04 1994-05-27 Fuji Photo Film Co Ltd Silver halide color photographic sensitive material and its processing method
US5817662A (en) 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5804584A (en) 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
WO1994015605A1 (en) 1993-01-14 1994-07-21 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
AU6092794A (en) 1993-01-19 1994-08-15 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
US5574057A (en) 1993-02-03 1996-11-12 University Of Utah Research Foundation Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent
US5401745A (en) 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5837703A (en) 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
US5589489A (en) 1993-12-15 1996-12-31 Zeneca Limited Cyclic amide derivatives for treating asthma
CA2113229C (en) 1994-01-11 1999-04-20 Mark Pines Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
AU1831395A (en) 1994-01-14 1995-08-01 Cell Therapeutics, Inc. Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
AU1967495A (en) 1994-02-18 1995-09-04 Cell Therapeutics, Inc. Intracellular signalling mediators
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5891879A (en) 1994-08-31 1999-04-06 Hadasit Medical Research Services & Development Co., Inc. Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
IL110831A (en) 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
IL112125A (en) 1994-12-22 1998-02-08 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions
US5843943A (en) * 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5908930A (en) 1995-03-15 1999-06-01 Pfizer Inc. 5,10-dihydropyrimdo 4,5-b!quinolin-4(1H)-one tyrosine kinase inhibitors
US5753664A (en) 1995-03-16 1998-05-19 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
WO1996039403A1 (en) 1995-06-05 1996-12-12 Neurogen Corporation 1-(n'-(arylalkylaminoalkyl)) aminoisoindoles as dopamine receptor ligands
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5518959A (en) * 1995-08-24 1996-05-21 Taiwan Semiconductor Manufacturing Company Method for selectively depositing silicon oxide spacer layers
KR100263434B1 (en) 1995-08-30 2000-08-01 오쓰카 요시미쓰 Process for producing quinazolin-4-one derivatives
AU4858596A (en) 1995-09-15 1997-04-01 Torrey Pines Institute For Molecular Studies Synthesis of quinazolinone libraries
US5783577A (en) 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
DE19546918A1 (en) 1995-12-15 1997-06-19 Bayer Ag Bicyclic heterocycles
TR199802296T2 (en) 1996-05-15 1999-02-22 Pfizer Inc. New 2,3 disubstituted-4 (3H)-quinazolinones
US5807662A (en) * 1996-05-20 1998-09-15 Konica Corporation Silver halide photographic light-sensitive material with tabular silicate particles
US6008010A (en) 1996-11-01 1999-12-28 University Of Pittsburgh Method and apparatus for holding cells
EP0946095A1 (en) 1996-12-17 1999-10-06 E.I. Du Pont De Nemours And Company Fungicidal quinazolinones
US6028075A (en) 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
US5852024A (en) 1997-02-11 1998-12-22 Hadasit Treatment and prevention of adhesions
US6060479A (en) 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
DE69831446T2 (en) 1997-06-09 2006-06-14 Pfizer Prod Inc Quinazolin-4-one AMPA antagonists
EP1001970B1 (en) 1997-06-25 2007-03-07 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
EP0903344B1 (en) 1997-08-21 2011-01-26 Shiseido Co., Ltd. Quinazolin-4-one derivatives, their preparation and their use as hair growth promoters or in external compositions for skin
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
EP1049475A4 (en) 1998-01-08 2003-06-04 Univ California MODULATORS OF THE KINESINE ENGINE DERIVED FROM THE SEA SPONGE $ i (ADOCIA)
WO1999046378A1 (en) * 1998-03-12 1999-09-16 Yamanouchi Pharmaceutical Co., Ltd. Novel g protein-coupled receptor proteins
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
EP1091960A1 (en) 1998-06-29 2001-04-18 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
AU5322399A (en) 1998-07-27 2000-02-21 President And Fellows Of Harvard College Method of high-throughput screening of molecules and compounds for their effectson biological and chemical processes
GB9911071D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
US6197488B1 (en) 1999-07-21 2001-03-06 Eastman Kodak Company Color photographic element containing a coupler releasing derivative with at least three heteroatoms with specific hydrophobicity
JP4831906B2 (en) 1999-08-27 2011-12-07 ケモセントリックス， インコーポレイテッド Heterocyclic compounds and methods for modulating CXCR3 function
WO2001019800A2 (en) 1999-09-16 2001-03-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
AU7654800A (en) 1999-09-28 2001-04-30 Merck Patent Gmbh Quinazolinones
WO2001023364A1 (en) 1999-09-28 2001-04-05 Merck Patent Gmbh Quinazolinones
EP1216243A1 (en) 1999-10-01 2002-06-26 Advanced Medicine, Inc. Quinazolinones and analogues and their use as local anesthetics
ATE327224T1 (en) 1999-10-27 2006-06-15 Cytokinetics Inc METHODS AND COMPOSITIONS USING CHINAZOLINONES
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
AR026748A1 (en) 1999-12-08 2003-02-26 Vertex Pharma A CASPASE INHIBITING COMPOUND, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, A METHOD FOR THE SYNTHESIS OF THE SAME AND AN INTERMEDIATE COMPOUND PARADICHA SYNTHESIS
ES2159488B1 (en) 2000-03-07 2002-04-16 Uriach & Cia Sa J PROCEDURE FOR THE PREPARATION OF PIRIMIDONE DERIVATIVES WITH ANTIFUNGIC ACTIVITY.
US20020082268A1 (en) 2000-03-20 2002-06-27 Yun Gao Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
US6613798B1 (en) 2000-03-30 2003-09-02 Curis, Inc. Small organic molecule regulators of cell proliferation
CA2404413C (en) 2000-03-30 2015-10-20 Curis, Inc. Small organic molecule regulators of cell proliferation
KR100851957B1 (en) 2000-06-09 2008-08-12 오에스아이 파마슈티컬스, 인코포레이티드 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
EP1174430A1 (en) 2000-07-20 2002-01-23 Universität Konstanz Process for the preparation of heterocycles by using C1-building blocks
HUP0300721A3 (en) * 2000-07-26 2006-02-28 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity, process for producing them, pharmaceutical compositions containing them and use thereof
CA2417631A1 (en) 2000-08-01 2003-01-29 Bayer Aktiengesellschaft Selective pde 2 inhibitors, used as medicaments for improving cognition
JP5000068B2 (en) 2000-08-11 2012-08-15 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Heterocyclic compounds useful as inhibitors of tyrosine kinases
MXPA03005152A (en) 2000-12-11 2004-10-14 Tularik Inc Cxcr3 antagonists.
JPWO2002094790A1 (en) * 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 Fused heterocyclic compounds and their pharmaceutical uses
CA2467916A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
US7262187B2 (en) 2001-12-06 2007-08-28 Merck & Co., Inc. Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor
ATE372341T1 (en) 2001-12-06 2007-09-15 Merck & Co Inc INHIBITORS OF MITOTIC KINESIN
JP4391825B2 (en) 2001-12-06 2009-12-24 メルク エンド カムパニー インコーポレーテッド Mitotic kinesin inhibitor
US7244723B2 (en) 2001-12-06 2007-07-17 Merck & Co., Inc. Substituted furopyrimidinones as a mitotic kinesin inhibitors
WO2003063800A2 (en) 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists
US20080070864A1 (en) 2002-03-07 2008-03-20 X-Ceptor Therapeutics, Inc. Quinazolinone Modulators Of Nuclear Receptors
WO2003079973A2 (en) 2002-03-08 2003-10-02 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2003299517A1 (en) 2002-05-23 2004-05-25 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2005530806A (en) 2002-05-23 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド Mitotic kinesin inhibitor
ES2282647T3 (en) 2002-06-14 2007-10-16 MERCK & CO., INC. INHIBITORS OF MITOTIC CINESINE.
CA2487489C (en) 2002-06-14 2010-11-23 Merck & Co., Inc. Mitotic kinesin inhibitors
TW200401770A (en) 2002-06-18 2004-02-01 Sankyo Co Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof
US20060134767A1 (en) 2002-07-08 2006-06-22 Buser-Doepner Carolyn A Mitotic kinesin binding site
WO2004006916A1 (en) 2002-07-10 2004-01-22 Applied Research Systems Ars Holding Nv Use of compounds for increasing spermatozoa motility
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
AU2003263323A1 (en) 2002-09-07 2004-03-29 Celltech R And D Limited Quinazolinone derivatives
EP1558083A4 (en) 2002-09-30 2008-04-16 Cytokinetics Inc Compounds, compositions, and methods
WO2004064741A2 (en) 2003-01-17 2004-08-05 Cytokinetics Inc. Compounds, compositions, and methods
ATE433448T1 (en) 2003-03-07 2009-06-15 Astrazeneca Ab CONDENSED HETEROCYCLES AND USES THEREOF

Patent Citations (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962244A (en) * 1971-01-23 1976-06-08 Hoechst Aktiengesellschaft Benzene sulfonyl ureas
US4011324A (en) * 1976-01-20 1977-03-08 Pfizer Inc. Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents
US5401766A (en) * 1980-08-30 1995-03-28 Hoechst Aktiengesellschaft Aminoacid derivatives, a process for their preparation, agents containing these compounds, and the use thereof
US5158959A (en) * 1980-08-30 1992-10-27 Hoechst Aktiengesellschaft Decahydroisoquinoline carboxylic acids
US4734419A (en) * 1985-10-07 1988-03-29 Fujisawa Pharmaceutical Co., Ltd. Quinazoline derivatives, compositions thereof and their use in treating diabetic complications
US4859670A (en) * 1986-03-21 1989-08-22 Hoechst Aktiengesellschaft 2-Azolylmethyl-2-aryl-1,3-dioxolanes and the salts thereof, agents containing same, and the use thereof
US5492915A (en) * 1990-07-24 1996-02-20 Rhone-Poulenc Rorer S.A. Substituted quinolyl compounds exhibiting selective leukotriene B4 antagonist activity
US5444061A (en) * 1991-03-19 1995-08-22 British Technology Group Limited Anti-cancer compounds
US5342944A (en) * 1993-07-19 1994-08-30 American Cyanamid Company Process for the preparation of 2-alkyl-3,5,6,7- or 8-substituted-4(3H)-quinazolinones
US20020198326A1 (en) * 1993-11-12 2002-12-26 Taizo Aoyama Polyolefin resin composition
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
US5948784A (en) * 1994-08-26 1999-09-07 Kyowa Hakko Kogyo Co., Ltd. Quinazoline derivatives
US6245768B1 (en) * 1995-06-05 2001-06-12 Neurogen Corporation 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands
US5892114A (en) * 1996-04-18 1999-04-06 Bayer Aktiengesellschaft Hetero-linked phenylglycinolamides
US5948775A (en) * 1997-03-19 1999-09-07 American Home Products Corporation 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
US6627755B1 (en) * 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
US5939421A (en) * 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
US20010046997A1 (en) * 1998-03-24 2001-11-29 Abraham Donald J. Allosteric inhibitors of pyruvate kinase
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6562831B1 (en) * 1999-10-27 2003-05-13 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6831085B1 (en) * 1999-10-27 2004-12-14 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6630479B1 (en) * 1999-10-27 2003-10-07 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US20020055519A1 (en) * 1999-10-29 2002-05-09 Thompson Wayne I. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US20030018038A1 (en) * 1999-10-29 2003-01-23 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US20020032207A1 (en) * 1999-10-29 2002-03-14 Wayne Thompson 2-Cyclohexyl quinazoline NMDA/NR2B antagonists
US20030139457A1 (en) * 2000-03-30 2003-07-24 Curis, Inc. Small organic molecule regulators of cell proliferation
US20030195211A1 (en) * 2000-04-25 2003-10-16 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US20040023996A1 (en) * 2000-06-21 2004-02-05 Finer Jeffrey T. Methods and compositions utilizing quinazolinones
US20020165221A1 (en) * 2000-10-13 2002-11-07 Baxter Anthony David Mediators of hedgehog signaling pathways, compositions and uses related thereto
US20040077667A1 (en) * 2000-12-11 2004-04-22 Nobuya Matsuoka Quinazolinone derivatives
US20030139398A1 (en) * 2001-04-09 2003-07-24 Hoekstra William J. Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
US20030091946A1 (en) * 2001-04-20 2003-05-15 Shigeki Uehira Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound
US6794379B2 (en) * 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
US20030220338A1 (en) * 2001-07-16 2003-11-27 Watkins Will J. Fungal efflux pump inhibitors
US20030144350A1 (en) * 2001-07-20 2003-07-31 Adipogenix, Inc. Fat accumulation-modulation compounds
US20030130293A1 (en) * 2001-09-05 2003-07-10 Bamdad Cynthia C. Compositions and methods of treatment of cancer
US20030119834A1 (en) * 2001-09-05 2003-06-26 Bamdad Cynthia C. Compositions and methods of treatment of cancer
US20040259826A1 (en) * 2001-11-07 2004-12-23 Fraley Mark E. Mitotic kinesin inhibitors
US20030171387A1 (en) * 2001-11-19 2003-09-11 Dongxu Sun Modulators of Rho C activity
US20040192913A1 (en) * 2001-11-20 2004-09-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
US20030166933A1 (en) * 2001-11-20 2003-09-04 Gustave Bergnes Process for the racemization of chiral quinazolinones
US6753428B2 (en) * 2001-11-20 2004-06-22 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
US20040067969A1 (en) * 2002-02-15 2004-04-08 Gustave Bergnes Syntheses of quinazolinones
US20030158188A1 (en) * 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20030158198A1 (en) * 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20030220356A1 (en) * 2002-04-04 2003-11-27 Prabha Ibrahim ABCA-1 elevating compounds
US20040077668A1 (en) * 2002-05-09 2004-04-22 Cytokinetics, Inc. Compounds, compositins, and methods
US20040077662A1 (en) * 2002-05-09 2004-04-22 Cytokinetics, Inc. Compounds, methods and compositions
US20040116438A1 (en) * 2002-05-23 2004-06-17 Pu-Ping Lu Compounds, compositions, and methods
US20040082567A1 (en) * 2002-06-14 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
US20040142949A1 (en) * 2002-07-23 2004-07-22 Gustave Bergnes Compounds, compositions, and methods
US20040048853A1 (en) * 2002-08-21 2004-03-11 Gustave Bergnes Compounds, compositions, and methods
US20040092561A1 (en) * 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
US20040242596A1 (en) * 2003-05-22 2004-12-02 Kim Kyoung S. Bicyclicpyrimidones and their use to treat diseases
US20050152940A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis

Cited By (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439254B2 (en) 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
US20050234037A1 (en) * 2003-12-08 2005-10-20 Gustave Bergnes Compounds, compositions, and methods
US20090124638A1 (en) * 2004-11-19 2009-05-14 Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
US8642604B2 (en) 2006-04-04 2014-02-04 The Regents Of The University Of California Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents
US20100009963A1 (en) * 2006-04-04 2010-01-14 The Regents Of The University Of California Kinase antagonists
US9493467B2 (en) 2006-04-04 2016-11-15 The Regents Of The University Of California PI3 kinase antagonists
US20110160232A1 (en) * 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
AU2009204483B2 (en) * 2008-01-04 2014-03-13 Intellikine, Llc Certain chemical entities, compositions and methods
US9822131B2 (en) 2008-01-04 2017-11-21 Intellikine Llc Certain chemical entities, compositions and methods
US9655892B2 (en) 2008-01-04 2017-05-23 Intellikine Llc Certain chemical entities, compositions and methods
CN104926815A (en) * 2008-01-04 2015-09-23 英特利凯恩有限责任公司 Certain Chemical Entities, Compositions And Methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR20100125240A (en) * 2008-01-04 2010-11-30 인텔리카인, 인크. Certain chemical entities, compositions and methods
KR101653842B1 (en) 2008-01-04 2016-09-02 인텔리카인, 엘엘씨 Certain chemical entities, compositions and methods
US20090312319A1 (en) * 2008-01-04 2009-12-17 Intellikine Certain chemical entities, compositions and methods
CN104926815B (en) * 2008-01-04 2017-11-03 英特利凯恩有限责任公司 Some chemical entities, composition and method
RU2716703C2 (en) * 2008-01-04 2020-03-16 Интелликайн ЭлЭлСи Certain chemical structures, compositions and methods
WO2009088986A1 (en) * 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
US9216982B2 (en) 2008-01-04 2015-12-22 Intellikine Llc Certain chemical entities, compositions and methods
AU2009204487C1 (en) * 2008-01-04 2014-10-16 Intellikine, Llc Certain chemical entities, compositions and methods
AU2009204487B2 (en) * 2008-01-04 2014-04-17 Intellikine, Llc Certain chemical entities, compositions and methods
WO2009088990A1 (en) * 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
US8703777B2 (en) 2008-01-04 2014-04-22 Intellikine Llc Certain chemical entities, compositions and methods
US8785456B2 (en) 2008-01-04 2014-07-22 Intellikine Llc Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US11433065B2 (en) 2008-01-04 2022-09-06 Intellikine Llc Certain chemical entities, compositions and methods
AU2014203687B2 (en) * 2008-01-04 2016-04-14 Intellikine Llc Certain chemical entities, compositions and methods
US9637492B2 (en) 2008-03-14 2017-05-02 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US20110077268A1 (en) * 2008-03-14 2011-03-31 Yi Liu Kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9828378B2 (en) 2008-07-08 2017-11-28 Intellikine Llc Kinase inhibitors and methods of use
US9629843B2 (en) 2008-07-08 2017-04-25 The Regents Of The University Of California MTOR modulators and uses thereof
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
US20110172228A1 (en) * 2008-07-08 2011-07-14 Pingda Ren Kinase inhibitors and methods of use
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US9296742B2 (en) 2008-09-26 2016-03-29 Intellikine Llc Heterocyclic kinase inhibitors
US9790228B2 (en) 2008-09-26 2017-10-17 Intellikine Llc Heterocyclic kinase inhibitors
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US20100184760A1 (en) * 2008-11-03 2010-07-22 Pingda Ren Benzoxazole kinase inhibitors and methods of use
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US8785454B2 (en) 2009-05-07 2014-07-22 Intellikine Llc Heterocyclic compounds and uses thereof
US9315505B2 (en) 2009-05-07 2016-04-19 Intellikine Llc Heterocyclic compounds and uses thereof
US9522146B2 (en) 2009-07-15 2016-12-20 Intellikine Llc Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US8569323B2 (en) 2009-07-15 2013-10-29 Intellikine, Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
US9206182B2 (en) 2009-07-15 2015-12-08 Intellikine Llc Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
KR101680406B1 (en) 2009-07-15 2016-11-29 인텔리카인, 엘엘씨 Certain chemical entities, compositions and methods
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9181221B2 (en) 2010-05-21 2015-11-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US9738644B2 (en) 2010-05-21 2017-08-22 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9388183B2 (en) 2010-11-10 2016-07-12 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
USRE46621E1 (en) 2011-01-10 2017-12-05 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9840505B2 (en) 2011-01-10 2017-12-12 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
US11312718B2 (en) 2011-01-10 2022-04-26 Infinity Pharmaceuticals, Inc. Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
US10550122B2 (en) 2011-01-10 2020-02-04 Infinity Pharmaceuticals, Inc. Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9290497B2 (en) 2011-01-10 2016-03-22 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9718815B2 (en) 2011-07-19 2017-08-01 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9605003B2 (en) 2011-07-19 2017-03-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9546180B2 (en) 2011-08-29 2017-01-17 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9115141B2 (en) 2011-08-29 2015-08-25 Infinity Pharmaceuticals, Inc. Substituted isoquinolinones and methods of treatment thereof
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9895373B2 (en) 2011-09-02 2018-02-20 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9255108B2 (en) 2012-04-10 2016-02-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9527847B2 (en) 2012-06-25 2016-12-27 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US11613544B2 (en) 2012-09-26 2023-03-28 The Regents Of The University Of California Substituted imidazo[1,5-a]pyrazines for modulation of IRE1
US10131668B2 (en) 2012-09-26 2018-11-20 The Regents Of The University Of California Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1
US10822340B2 (en) 2012-09-26 2020-11-03 The Regents Of The University Of California Substituted imidazolopyrazine compounds and methods of using same
US12213983B2 (en) 2012-11-01 2025-02-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US10329299B2 (en) 2013-10-04 2019-06-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9828377B2 (en) 2013-10-04 2017-11-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US12152032B2 (en) 2013-10-04 2024-11-26 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9359365B2 (en) 2013-10-04 2016-06-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11541059B2 (en) 2014-03-19 2023-01-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10675286B2 (en) 2014-03-19 2020-06-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11944631B2 (en) 2014-04-16 2024-04-02 Infinity Pharmaceuticals, Inc. Combination therapies
US11110096B2 (en) 2014-04-16 2021-09-07 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10941162B2 (en) 2014-10-03 2021-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10253047B2 (en) 2014-10-03 2019-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11247995B2 (en) 2015-09-14 2022-02-15 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US11939333B2 (en) 2015-09-14 2024-03-26 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11147818B2 (en) 2016-06-24 2021-10-19 Infinity Pharmaceuticals, Inc. Combination therapies

Also Published As

Publication number Publication date
AU2003236527A8 (en) 2003-12-31
AU2003236527A1 (en) 2003-12-31
WO2003106426A1 (en) 2003-12-24
US7041676B2 (en) 2006-05-09
US20040082567A1 (en) 2004-04-29
EP1556357A4 (en) 2006-09-13
CA2489367A1 (en) 2003-12-24
EP1556357A1 (en) 2005-07-27
JP2005538062A (en) 2005-12-15

Similar Documents

Publication Publication Date Title
US7041676B2 (en) Compounds, compositions, and methods
US7439254B2 (en) Compounds, compositions, and methods
US7528137B2 (en) Compounds, compositions, and methods
US7482343B2 (en) Compounds, methods and compositions
US20070254870A1 (en) Compounds, compositions and methods
US20070149500A1 (en) Compounds, compositions, and methods
US6949538B2 (en) Compounds, compositions, and methods
US7476743B2 (en) Compounds, compositions, and methods
US20080312310A1 (en) Compounds, Compositions and Methods
US20080021079A1 (en) Compounds, Compositions, and Methods
US7271167B2 (en) Compounds, compositions, and methods
US20050165089A1 (en) Compounds, compositions and methods
US20050197327A1 (en) Compounds, compositions, and methods
US20070032536A1 (en) Compounds, compositions and methods
US20070232597A1 (en) Compounds, Compositions, and Methods
US20070066591A1 (en) Compounds, compositions, and methods

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: CYTOKINETICS, INCORPORATED, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SMITHKLINE BEECHAM CORPORATION;REEL/FRAME:022681/0551

Effective date: 20090224

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载